LayerRx Mapping ID
240
Slot System
Featured Buckets
Featured Buckets Admin
Medscape Lead Concept
8

Sports Purpura From Floorball, Indoor Climbing, and Archery

Article Type
Changed
Display Headline
Sports Purpura From Floorball, Indoor Climbing, and Archery

To the Editor:

Sports purpura can be broken down into different types including traumatic purpura,1 exercise-induced cutaneous vasculitis,2 occurrence of coincidental systemic purpura,3 and other conditions.4-6 Traumatic purpura results from brutal contact with an opponent, the court, the equipment, or the ball. Three cases of sports purpura related to equipment and balls are reported.

An otherwise healthy 27-year-old woman presented with multiple ecchymotic round patches on her legs. The largest patch was 70 mm and displayed a heterogeneous Swiss cheese–like pattern with discrete whiter round areas within the patch (Figure 1). She reported that she played as a defender in a second division floorball team weekly, acknowledging frequent body contacts and being hit on the legs with the sticks and balls. Purpura was diagnosed due to hits from the floorball.

A 32-year-old healthy man presented with purpuric petechiae of the left palm after indoor climbing. He had been regularly climbing indoors for 3 years and denied a history of similar eruptions. The lesions were painless, noninfiltrated, and did not disappear after pressure (Figure 2). Lesions presumably were due to repeated friction on the climbing hold. Petechiae took a transiently golden hue before resolving within a week.

Figure 1. Multiple ecchymotic patches including the largest patch, which displayed a heterogeneous Swiss cheese–like pattern from the ball design.
 
Figure 2. Palmar petechiae after an indoor climbing session.

A 26-year-old right-handed woman injured the left forearm while practicing target archery. She was not wearing an arm guard at the time of the injury. Once released, the bowstring scraped the volar aspect of the forearm, causing a painful warm ecchymotic and swollen plaque. She denied neurologic or vascular symptoms. The hematoma rapidly evolved from red to blue (Figure 3) and spontaneously resolved within weeks.

 
Figure 3. An ecchymotic plaque on the forearm from an archery bowstring immediately after the trauma occurred (A) and after 24-hour evolution (B).

Purpura related to the high-velocity impact of sport balls has been previously reported with ping-pong,7 paintball,8,9 racquetball, squash,10 and baseball. Floorball, one of the most popular team sports in Finland, is played indoors and resembles ice hockey. The players use graphite compound sticks and a light hollow plastic ball. Except for the goalkeeper, players do not wear specific protective gear. Accidental body contact, including a direct hit from the floorball stick or ball, are frequent.11 The ball weighs 23 g, measures 72 mm in diameter, and has 26 holes that are 11 mm in diameter. The fastest shot was recorded at 127 miles per hour.12 The cutaneous imprint from the ball impact on bare skin, as shown with patient 1, initially is annular,8-10 but the bruise later takes an unusual design due to the peculiar shape of the ball. This complication is no stranger to floorball players but has been rarely reported. The diagnosis is easy, the condition is benign and asymptomatic, and it resolves when the season is over; therefore, players commonly will not seek medical attention. Of note, lower limb injuries, including joint sprains, muscle strains, and soft-tissue contusions, are frequent in female athletes.11 Additional causes of purpura include collision with another player or with boards and stick hits.

Palmar petechiae from indoor climbing is similar to black palm from weight lifting.13 Although the typical black discoloration is absent, the mechanisms of friction and brutal trauma, clinical presentation, and evolution are similar.

Lastly, archery-induced hematomas are caused by the absence of an arm guard, which protects the wrist and forearm when the string snaps back.14 This complication is not often reported but is known by archers. Because archers usually wear protective gear, these injuries are expected to occur in novices or when safety measures are not respected.

References

1. Aguayo-Leiva I, Vano-Galvan S, Arrazola JM. A purpuric rash. Aust Fam Physician. 2009;38:889-890.

2. Ramelet AA. Exercise-induced vasculitis. J Eur Acad Dermatol Venereol. 2006;20:423-427.

3. Leonard JC, Rieger M. Idiopathic thrombocytopenic purpura presenting in a high school football player: a case report. J Athl Train. 1998;33:269-270.

4. Nordlind K, Bondesson L, Johansson SG, et al. Purpura provoked by cold exposure in a skier. Dermatologica. 1983;167:101-103.

5. Latenser BA, Hempstead RW. Exercise-associated solar purpura in an atypical location. Cutis. 1985;35:365-366.

6. Allan SJ, Humphreys F, Buxton PK. Annular purpura and step aerobics. Clin Exp Dermatol. 1994;19:418.

7. Scott MJ Jr, Scott MJ 3rd. Ping pong patches. Cutis. 1989;43:363-364.

8. Aboutalebi S, Stetson CL. Paintball purpura. J Am Acad Dermatol. 2005;53:901-902.

9. Levsky ME, Crowe M. What is your diagnosis? paintball purpura. Cutis. 2005;75:148, 157-158.

10. Barazi H, Adams BB. Sports purpura. Int J Dermatol. 2006;45:1443.

11. Pasanen K, Parkkari J, Kannus P, et al. Injury risk in female floorball: a prospective one-season follow-up [published online ahead of print May 9, 2007]. Scand J Med Sci Sports. 2008;18:49-54.

12. New world record. Floorball Central Web site. http://www.floorballcentral.com/2010/11/new-world -record.html. Published November 5, 2010. Accessed April 8, 2015.

13. Izumi AK. Letter: pigmented palmar petechiae (black palm). Arch Dermatol. 1974;109:261.

14. Rayan GM. Archery-related injuries of the hand, forearm, and elbow. South Med J. 1992;85:961-964.

Article PDF
Author and Disclosure Information

Nicolas Kluger, MD, PhD

From the University of Helsinki and Helsinki University Central Hospital, Finland.

The author reports no conflict of interest.

Correspondence: Nicolas Kluger, MD, PhD, 00029 HUS, Helsinki, Finland (nicolaskluger@yahoo.fr).

Issue
Cutis - 95(5)
Publications
Topics
Page Number
E3-E4
Legacy Keywords
sport, purpura, trauma, climbing, floorball, archery, hematoma
Sections
Author and Disclosure Information

Nicolas Kluger, MD, PhD

From the University of Helsinki and Helsinki University Central Hospital, Finland.

The author reports no conflict of interest.

Correspondence: Nicolas Kluger, MD, PhD, 00029 HUS, Helsinki, Finland (nicolaskluger@yahoo.fr).

Author and Disclosure Information

Nicolas Kluger, MD, PhD

From the University of Helsinki and Helsinki University Central Hospital, Finland.

The author reports no conflict of interest.

Correspondence: Nicolas Kluger, MD, PhD, 00029 HUS, Helsinki, Finland (nicolaskluger@yahoo.fr).

Article PDF
Article PDF
Related Articles

To the Editor:

Sports purpura can be broken down into different types including traumatic purpura,1 exercise-induced cutaneous vasculitis,2 occurrence of coincidental systemic purpura,3 and other conditions.4-6 Traumatic purpura results from brutal contact with an opponent, the court, the equipment, or the ball. Three cases of sports purpura related to equipment and balls are reported.

An otherwise healthy 27-year-old woman presented with multiple ecchymotic round patches on her legs. The largest patch was 70 mm and displayed a heterogeneous Swiss cheese–like pattern with discrete whiter round areas within the patch (Figure 1). She reported that she played as a defender in a second division floorball team weekly, acknowledging frequent body contacts and being hit on the legs with the sticks and balls. Purpura was diagnosed due to hits from the floorball.

A 32-year-old healthy man presented with purpuric petechiae of the left palm after indoor climbing. He had been regularly climbing indoors for 3 years and denied a history of similar eruptions. The lesions were painless, noninfiltrated, and did not disappear after pressure (Figure 2). Lesions presumably were due to repeated friction on the climbing hold. Petechiae took a transiently golden hue before resolving within a week.

Figure 1. Multiple ecchymotic patches including the largest patch, which displayed a heterogeneous Swiss cheese–like pattern from the ball design.
 
Figure 2. Palmar petechiae after an indoor climbing session.

A 26-year-old right-handed woman injured the left forearm while practicing target archery. She was not wearing an arm guard at the time of the injury. Once released, the bowstring scraped the volar aspect of the forearm, causing a painful warm ecchymotic and swollen plaque. She denied neurologic or vascular symptoms. The hematoma rapidly evolved from red to blue (Figure 3) and spontaneously resolved within weeks.

 
Figure 3. An ecchymotic plaque on the forearm from an archery bowstring immediately after the trauma occurred (A) and after 24-hour evolution (B).

Purpura related to the high-velocity impact of sport balls has been previously reported with ping-pong,7 paintball,8,9 racquetball, squash,10 and baseball. Floorball, one of the most popular team sports in Finland, is played indoors and resembles ice hockey. The players use graphite compound sticks and a light hollow plastic ball. Except for the goalkeeper, players do not wear specific protective gear. Accidental body contact, including a direct hit from the floorball stick or ball, are frequent.11 The ball weighs 23 g, measures 72 mm in diameter, and has 26 holes that are 11 mm in diameter. The fastest shot was recorded at 127 miles per hour.12 The cutaneous imprint from the ball impact on bare skin, as shown with patient 1, initially is annular,8-10 but the bruise later takes an unusual design due to the peculiar shape of the ball. This complication is no stranger to floorball players but has been rarely reported. The diagnosis is easy, the condition is benign and asymptomatic, and it resolves when the season is over; therefore, players commonly will not seek medical attention. Of note, lower limb injuries, including joint sprains, muscle strains, and soft-tissue contusions, are frequent in female athletes.11 Additional causes of purpura include collision with another player or with boards and stick hits.

Palmar petechiae from indoor climbing is similar to black palm from weight lifting.13 Although the typical black discoloration is absent, the mechanisms of friction and brutal trauma, clinical presentation, and evolution are similar.

Lastly, archery-induced hematomas are caused by the absence of an arm guard, which protects the wrist and forearm when the string snaps back.14 This complication is not often reported but is known by archers. Because archers usually wear protective gear, these injuries are expected to occur in novices or when safety measures are not respected.

To the Editor:

Sports purpura can be broken down into different types including traumatic purpura,1 exercise-induced cutaneous vasculitis,2 occurrence of coincidental systemic purpura,3 and other conditions.4-6 Traumatic purpura results from brutal contact with an opponent, the court, the equipment, or the ball. Three cases of sports purpura related to equipment and balls are reported.

An otherwise healthy 27-year-old woman presented with multiple ecchymotic round patches on her legs. The largest patch was 70 mm and displayed a heterogeneous Swiss cheese–like pattern with discrete whiter round areas within the patch (Figure 1). She reported that she played as a defender in a second division floorball team weekly, acknowledging frequent body contacts and being hit on the legs with the sticks and balls. Purpura was diagnosed due to hits from the floorball.

A 32-year-old healthy man presented with purpuric petechiae of the left palm after indoor climbing. He had been regularly climbing indoors for 3 years and denied a history of similar eruptions. The lesions were painless, noninfiltrated, and did not disappear after pressure (Figure 2). Lesions presumably were due to repeated friction on the climbing hold. Petechiae took a transiently golden hue before resolving within a week.

Figure 1. Multiple ecchymotic patches including the largest patch, which displayed a heterogeneous Swiss cheese–like pattern from the ball design.
 
Figure 2. Palmar petechiae after an indoor climbing session.

A 26-year-old right-handed woman injured the left forearm while practicing target archery. She was not wearing an arm guard at the time of the injury. Once released, the bowstring scraped the volar aspect of the forearm, causing a painful warm ecchymotic and swollen plaque. She denied neurologic or vascular symptoms. The hematoma rapidly evolved from red to blue (Figure 3) and spontaneously resolved within weeks.

 
Figure 3. An ecchymotic plaque on the forearm from an archery bowstring immediately after the trauma occurred (A) and after 24-hour evolution (B).

Purpura related to the high-velocity impact of sport balls has been previously reported with ping-pong,7 paintball,8,9 racquetball, squash,10 and baseball. Floorball, one of the most popular team sports in Finland, is played indoors and resembles ice hockey. The players use graphite compound sticks and a light hollow plastic ball. Except for the goalkeeper, players do not wear specific protective gear. Accidental body contact, including a direct hit from the floorball stick or ball, are frequent.11 The ball weighs 23 g, measures 72 mm in diameter, and has 26 holes that are 11 mm in diameter. The fastest shot was recorded at 127 miles per hour.12 The cutaneous imprint from the ball impact on bare skin, as shown with patient 1, initially is annular,8-10 but the bruise later takes an unusual design due to the peculiar shape of the ball. This complication is no stranger to floorball players but has been rarely reported. The diagnosis is easy, the condition is benign and asymptomatic, and it resolves when the season is over; therefore, players commonly will not seek medical attention. Of note, lower limb injuries, including joint sprains, muscle strains, and soft-tissue contusions, are frequent in female athletes.11 Additional causes of purpura include collision with another player or with boards and stick hits.

Palmar petechiae from indoor climbing is similar to black palm from weight lifting.13 Although the typical black discoloration is absent, the mechanisms of friction and brutal trauma, clinical presentation, and evolution are similar.

Lastly, archery-induced hematomas are caused by the absence of an arm guard, which protects the wrist and forearm when the string snaps back.14 This complication is not often reported but is known by archers. Because archers usually wear protective gear, these injuries are expected to occur in novices or when safety measures are not respected.

References

1. Aguayo-Leiva I, Vano-Galvan S, Arrazola JM. A purpuric rash. Aust Fam Physician. 2009;38:889-890.

2. Ramelet AA. Exercise-induced vasculitis. J Eur Acad Dermatol Venereol. 2006;20:423-427.

3. Leonard JC, Rieger M. Idiopathic thrombocytopenic purpura presenting in a high school football player: a case report. J Athl Train. 1998;33:269-270.

4. Nordlind K, Bondesson L, Johansson SG, et al. Purpura provoked by cold exposure in a skier. Dermatologica. 1983;167:101-103.

5. Latenser BA, Hempstead RW. Exercise-associated solar purpura in an atypical location. Cutis. 1985;35:365-366.

6. Allan SJ, Humphreys F, Buxton PK. Annular purpura and step aerobics. Clin Exp Dermatol. 1994;19:418.

7. Scott MJ Jr, Scott MJ 3rd. Ping pong patches. Cutis. 1989;43:363-364.

8. Aboutalebi S, Stetson CL. Paintball purpura. J Am Acad Dermatol. 2005;53:901-902.

9. Levsky ME, Crowe M. What is your diagnosis? paintball purpura. Cutis. 2005;75:148, 157-158.

10. Barazi H, Adams BB. Sports purpura. Int J Dermatol. 2006;45:1443.

11. Pasanen K, Parkkari J, Kannus P, et al. Injury risk in female floorball: a prospective one-season follow-up [published online ahead of print May 9, 2007]. Scand J Med Sci Sports. 2008;18:49-54.

12. New world record. Floorball Central Web site. http://www.floorballcentral.com/2010/11/new-world -record.html. Published November 5, 2010. Accessed April 8, 2015.

13. Izumi AK. Letter: pigmented palmar petechiae (black palm). Arch Dermatol. 1974;109:261.

14. Rayan GM. Archery-related injuries of the hand, forearm, and elbow. South Med J. 1992;85:961-964.

References

1. Aguayo-Leiva I, Vano-Galvan S, Arrazola JM. A purpuric rash. Aust Fam Physician. 2009;38:889-890.

2. Ramelet AA. Exercise-induced vasculitis. J Eur Acad Dermatol Venereol. 2006;20:423-427.

3. Leonard JC, Rieger M. Idiopathic thrombocytopenic purpura presenting in a high school football player: a case report. J Athl Train. 1998;33:269-270.

4. Nordlind K, Bondesson L, Johansson SG, et al. Purpura provoked by cold exposure in a skier. Dermatologica. 1983;167:101-103.

5. Latenser BA, Hempstead RW. Exercise-associated solar purpura in an atypical location. Cutis. 1985;35:365-366.

6. Allan SJ, Humphreys F, Buxton PK. Annular purpura and step aerobics. Clin Exp Dermatol. 1994;19:418.

7. Scott MJ Jr, Scott MJ 3rd. Ping pong patches. Cutis. 1989;43:363-364.

8. Aboutalebi S, Stetson CL. Paintball purpura. J Am Acad Dermatol. 2005;53:901-902.

9. Levsky ME, Crowe M. What is your diagnosis? paintball purpura. Cutis. 2005;75:148, 157-158.

10. Barazi H, Adams BB. Sports purpura. Int J Dermatol. 2006;45:1443.

11. Pasanen K, Parkkari J, Kannus P, et al. Injury risk in female floorball: a prospective one-season follow-up [published online ahead of print May 9, 2007]. Scand J Med Sci Sports. 2008;18:49-54.

12. New world record. Floorball Central Web site. http://www.floorballcentral.com/2010/11/new-world -record.html. Published November 5, 2010. Accessed April 8, 2015.

13. Izumi AK. Letter: pigmented palmar petechiae (black palm). Arch Dermatol. 1974;109:261.

14. Rayan GM. Archery-related injuries of the hand, forearm, and elbow. South Med J. 1992;85:961-964.

Issue
Cutis - 95(5)
Issue
Cutis - 95(5)
Page Number
E3-E4
Page Number
E3-E4
Publications
Publications
Topics
Article Type
Display Headline
Sports Purpura From Floorball, Indoor Climbing, and Archery
Display Headline
Sports Purpura From Floorball, Indoor Climbing, and Archery
Legacy Keywords
sport, purpura, trauma, climbing, floorball, archery, hematoma
Legacy Keywords
sport, purpura, trauma, climbing, floorball, archery, hematoma
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Yoga for Dermatologic Conditions

Article Type
Changed
Display Headline
Yoga for Dermatologic Conditions

Regardless of its spiritual origins, yoga has become a popular way of reaching mind and body well-being with nearly 30 million people practicing regularly worldwide.1 Yoga, which is the combination of physical postures, controlled breathing, and meditation or mindfulness, has long been used in complementary and alternative medicine around the world and recently has gained popularity as a therapeutic practice, with nearly 14 million Americans reporting that yoga was recommended to them by a physician or therapist.2,3 Studies suggest that people who participate in even brief yoga programs may see improvements in anxiety, somatic stress and discomfort, health-related quality of life, and self-rated sleep quality, all benefits that can help medical conditions, especially those that are dermatologic in nature.4,5

Stress and Dermatologic Conditions

The interaction between the mind, skin, and body is well known. Research in psychoneuroimmunology, the interaction between psychological processes and the nervous and immune systems, has examined the role of neuropeptides, hormones, and neurotransmitters in psychodermatological disorders. The correlation between neuroimmunological pathways and skin inflammation is now well recognized, specifically the interactions between the brain and skin underlying many dermatological diseases (eg, acne, alopecia areata, various types of eczema and dermatitis, oral and genital herpes, hyperhidrosis, pruritus, psoriasis, rosacea, urticaria, warts, breaking or ridging of the nails).6-9

Two biological systems are known to be affected by the systemic stress response: (1) the hypothalamic-pituitary-adrenal axis, which regulates the release of adrenocorticotropin, ß-endorphin, and cortisol, and (2) the sympathoadrenal medullary system, which regulates the release of catecholamines (eg, epinephrine, norepinephrine).7 Cortisol and catecholamines have been shown to have potent effects on the immune system as well as the inflammatory response.9 Additionally, it has been shown that cutaneous sensory nerve terminals release neuropeptides, including calcitonin gene-related peptide and substance P, both of which have different effects on the local inflammatory response.10,11

Psychological stress is well known to trigger many dermatologic conditions, but it also may lead to abnormal skin barrier function.12 The mechanism in which skin barrier function is affected appears to involve a stress-induced increase of endogenous glucocorticoids, which may consequently disrupt skin barrier function and recovery rates, stratum corneum cohesion, and epidermal antimicrobial function.13,14

Atopic dermatitis, for example, is classified as a psychophysiological disorder. Although it is not caused by stress, atopic dermatitis has been described to be precipitated or exacerbated by stress in patients.15 In fact, it was found that stressful life events preceded the onset of itching in more than 70% of patients with atopic dermatitis,16 which is especially relevant, as there is no cure and patients often experience a lifelong struggle with the condition. Additionally, stress mediates the degranulation of mast cells via corticotropin-releasing hormone and neuropeptides, and the upregulation of mast cell corticotropin-releasing hormone receptors supporting its putative role in the pathogenesis of urticaria.9,17 Furthermore, the increase in cortisol also has been described in the exacerbation of acne during times of stress.18

Psychological factors affect the management of skin conditions in more than one-third of reported dermatology patients; therefore, it is important to consider these factors in the treatment of chronic dermatological conditions, especially when they are inquired by the patient.19,20

Yoga Benefits in the Literature

The therapeutic potential of yoga has been explored in a growing number of randomized controlled trials to date.21 A recently published bibliometric analysis provided a comprehensive review of the characteristics of the randomized yoga trials available in the literature.22 The review included 366 full-text articles, with the 2 earliest studies published in 1975 and nearly 90% published within the last decade. In addition to healthy patients, it was found these randomized controlled yoga trials most commonly enrolled patients with breast cancer, depression, asthma, and type 2 diabetes mellitus.22 Another study examined psychological (eg, self-rated stress and stress behavior, anger, exhaustion, quality of life) and physiological (eg, blood pressure, heart rate, urinary catecholamines, salivary cortisol) measurements obtained before and after a 10-session yoga program that participants completed over a 4-month period, with results showing significant improvements (P<.05) on almost all stress-related subjective and physiological variables. Results were comparable with cognitive behavioral therapy.23

Not only has it been shown that yoga helps patients on a psychological level, but a recent study reported that 90-minute sessions of mindfulness meditation and gentle Hatha yoga over an 8-week period led to observable benefits on a cellular level, as telomere length was maintained in distressed breast cancer survivors compared to decreases in telomere length in the control group with patients who solely participated in a stress management seminar.24 To date, there are no known studies examining the effects of yoga on patients with skin cancer. However, a few studies have specifically examined the effect of yoga in managing non–cancer-related dermatologic issues. Specifically, one small study of psoriasis patients found that those who listened to mindfulness meditation tapes while undergoing standard phototherapy (psoralen plus UVA) healed faster than those who underwent phototherapy treatment alone.25

 

 

Because some dermatologic problems have comorbidities and increased risk factors of other medical problems, such as psoriasis with psoriatic arthritis and metabolic diseases (eg, abdominal obesity, diabetes, nonalcoholic fatty liver disease, dyslipidemia, metabolic syndrome, chronic kidney disease), it is even more pertinent to recommend approaches for healthy mind and body well-being as a supplement to medical care.26

Final Thoughts

With accurate diagnosis by a dermatologist, appropriate conventional treatments can improve dermatologic problems. These treatments alone can reduce patients’ stress and improve skin, hair, and nail conditions; however, if it is clear that stress is interfering with a patient’s overall well-being and ability to cope with his/her dermatologic condition, concurrent stress management interventions may be warranted. In some instances, recommending yoga sessions, mindful meditation, or breathing exercises may help, while in others referral to a mental health professional may be necessary.

Beyond the direct physiological effects of stress, it also is worth mentioning that patients who deal with stress also tend to scratch, pick, or irritate their skin more and often lack the motivation to adhere to skin care regimens or treatments, again supporting the idea that our approach in managing these patients must be multifaceted. As dermatologists in training, residents should be cognizant of the potential psychological sequelae of some dermatologic problems and be aware of the possible use of supplemental interventions by our patients.

References

1. Dangerfield A. Yoga wars. BBC News. http://news.bbc.co.uk/1/hi/7844691.stm. Published January 23, 2009. Accessed March 25, 2015.

2. Yoga Journal releases 2012 yoga in America market study [press release]. San Francisco, CA: Yoga Journal; December 6, 2012.

3. De Michaelis E. A History of Modern Yoga: Patanjali and Western Esotericism. London, United Kingdom: A&C Black; 2005.

4. Telles S, Singh N, Yadav A, et al. Effect of yoga on different aspects of mental health. Indian J Physiol Pharmacol. 2012;56:245-254.

5. Rodriguez-Vallecillo E, Woodbury-Fariña MA. Dermatological manifestations of stress in normal and psychiatric populations. Psychiatr Clin North Am. 2014;37:625-651.

6. Stander S, Raap U, Weisshaar E, et al. Pathogenesis of pruritus. J Dtsch Dermatol Ges. 2011;9:456-463.

7. Arck PC, Slominski A, Theoharides TC, et al. Neuroimmunology of stress: skin takes center stage. J Invest Dermatol. 2006;126:1697-1704.

8. Recognizing the mind-skin connection. Harvard Health Publications Web site. http://www.health.harvard.edu/newsletter_article/Recognizing_the_mind-skin_connection. Published November 1, 2006. Accessed March 31, 2015.

9. Tausk F, Elenkov I, Moynihan J. Psychoneuroimmunology. Dermatol Ther. 2008;21:22-31.

10. Pavlovic S, Liezmann C, Blois SM, et al. Substance P is a key mediator of stress-induced protection from allergic sensitization via modified antigen presentation. J Immunol. 2011;186:848-855.

11. Toyoda M, Nakamura M, Makino T, et al. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol. 2002;147:71-79.

12. Koo JYM, Lee CS. General approach to evaluating psychodermatological disorders. In: Koo JYM, Lee CS, eds. Psychocutaneous Medicine. New York, NY: Marcel Dekker; 2003:1-29.

13. Garg A, Chren MM, Sands LP, et al. Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders. Arch Dermatol. 2001;137:53-59.

14. Elias PM, Sun R, Eder AR, et al. Treating atopic dermatitis at the source: corrective barrier repair therapy based upon new pathogenic insights. Expert Rev Dermatol. 2013;8:27-36.

15. Morren MA, Przybilla B, Bamelis M, et al. Atopic dermatitis: triggering factors. J Am Acad Dermatol. 1994;31:467-473.

16. Faulstich ME, Williamson DA. An overview of atopic dermatitis: toward a bio-behavioural integration. J Psychosom Res. 1985;29:647-654.

17. Theoharides TC, Donelan JM, Papadopoulou N, et al. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25:563-568.

18. Suh DH, Kwon HH. What’s new in the physiopathology of acne [published online ahead of print Jan 24, 2015]? Br J Dermatol. doi:10.1111/bjd.13634.

19. Picardi A, Mazzotti E, Pasquini P. Prevalence and correlates of suicidal ideation among patients with skin disease. J Am Acad Dermatol. 2006;54:420-426.

20. Ponarovsky B, Amital D, Lazarov A, et al. Anxiety and depression in patients with allergic and non-allergic cutaneous disorders. Int J Dermatol. 2011;50:1217-1222.

21. Khalsa SB. Yoga as a therapeutic intervention: a bibliometric analysis of published research studies. Indian J Physiol Pharmacol. 2004;48:269-285.

22. Cramer H, Lauche R, Dobos G. Characteristics of randomized controlled trials of yoga: a bibliometric analysis. BMC Complement Altern Med. 2014;14:328.

23. Granath J, Ingvarsson S, von Thiele U, et al. Stress management: a randomized study of cognitive behavioural therapy and yoga. Cogn Behav Ther. 2006;35:3-10.

24. Carlson LE, Beattie TL, Giese-Davis J, et al. Mindfulness-based cancer recovery and supportive-expressive therapy maintain telomere length relative to controls in distressed breast cancer survivors. Cancer. 2015;121:476-484.

25. Kabat-Zinn J, Wheeler E, Light T, et al. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom Med. 1998;60:625-632.

26. Gisondi P, Galvan A, Idolazzi L, et al. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front Med (Lausanne). 2015;2:1.

Article PDF
Author and Disclosure Information

Sheila Jalalat, MD

From Presence Health Resurrection Medical Center, Chicago, Illinois.

The author reports no conflict of interest.

Correspondence: Sheila Jalalat, MD (sjalalat@gmail.com).

Issue
Cutis - 95(4)
Publications
Topics
Page Number
E23-E25
Legacy Keywords
Yoga, alternative medicine, Dermatologic Conditions,
Sections
Author and Disclosure Information

Sheila Jalalat, MD

From Presence Health Resurrection Medical Center, Chicago, Illinois.

The author reports no conflict of interest.

Correspondence: Sheila Jalalat, MD (sjalalat@gmail.com).

Author and Disclosure Information

Sheila Jalalat, MD

From Presence Health Resurrection Medical Center, Chicago, Illinois.

The author reports no conflict of interest.

Correspondence: Sheila Jalalat, MD (sjalalat@gmail.com).

Article PDF
Article PDF

Regardless of its spiritual origins, yoga has become a popular way of reaching mind and body well-being with nearly 30 million people practicing regularly worldwide.1 Yoga, which is the combination of physical postures, controlled breathing, and meditation or mindfulness, has long been used in complementary and alternative medicine around the world and recently has gained popularity as a therapeutic practice, with nearly 14 million Americans reporting that yoga was recommended to them by a physician or therapist.2,3 Studies suggest that people who participate in even brief yoga programs may see improvements in anxiety, somatic stress and discomfort, health-related quality of life, and self-rated sleep quality, all benefits that can help medical conditions, especially those that are dermatologic in nature.4,5

Stress and Dermatologic Conditions

The interaction between the mind, skin, and body is well known. Research in psychoneuroimmunology, the interaction between psychological processes and the nervous and immune systems, has examined the role of neuropeptides, hormones, and neurotransmitters in psychodermatological disorders. The correlation between neuroimmunological pathways and skin inflammation is now well recognized, specifically the interactions between the brain and skin underlying many dermatological diseases (eg, acne, alopecia areata, various types of eczema and dermatitis, oral and genital herpes, hyperhidrosis, pruritus, psoriasis, rosacea, urticaria, warts, breaking or ridging of the nails).6-9

Two biological systems are known to be affected by the systemic stress response: (1) the hypothalamic-pituitary-adrenal axis, which regulates the release of adrenocorticotropin, ß-endorphin, and cortisol, and (2) the sympathoadrenal medullary system, which regulates the release of catecholamines (eg, epinephrine, norepinephrine).7 Cortisol and catecholamines have been shown to have potent effects on the immune system as well as the inflammatory response.9 Additionally, it has been shown that cutaneous sensory nerve terminals release neuropeptides, including calcitonin gene-related peptide and substance P, both of which have different effects on the local inflammatory response.10,11

Psychological stress is well known to trigger many dermatologic conditions, but it also may lead to abnormal skin barrier function.12 The mechanism in which skin barrier function is affected appears to involve a stress-induced increase of endogenous glucocorticoids, which may consequently disrupt skin barrier function and recovery rates, stratum corneum cohesion, and epidermal antimicrobial function.13,14

Atopic dermatitis, for example, is classified as a psychophysiological disorder. Although it is not caused by stress, atopic dermatitis has been described to be precipitated or exacerbated by stress in patients.15 In fact, it was found that stressful life events preceded the onset of itching in more than 70% of patients with atopic dermatitis,16 which is especially relevant, as there is no cure and patients often experience a lifelong struggle with the condition. Additionally, stress mediates the degranulation of mast cells via corticotropin-releasing hormone and neuropeptides, and the upregulation of mast cell corticotropin-releasing hormone receptors supporting its putative role in the pathogenesis of urticaria.9,17 Furthermore, the increase in cortisol also has been described in the exacerbation of acne during times of stress.18

Psychological factors affect the management of skin conditions in more than one-third of reported dermatology patients; therefore, it is important to consider these factors in the treatment of chronic dermatological conditions, especially when they are inquired by the patient.19,20

Yoga Benefits in the Literature

The therapeutic potential of yoga has been explored in a growing number of randomized controlled trials to date.21 A recently published bibliometric analysis provided a comprehensive review of the characteristics of the randomized yoga trials available in the literature.22 The review included 366 full-text articles, with the 2 earliest studies published in 1975 and nearly 90% published within the last decade. In addition to healthy patients, it was found these randomized controlled yoga trials most commonly enrolled patients with breast cancer, depression, asthma, and type 2 diabetes mellitus.22 Another study examined psychological (eg, self-rated stress and stress behavior, anger, exhaustion, quality of life) and physiological (eg, blood pressure, heart rate, urinary catecholamines, salivary cortisol) measurements obtained before and after a 10-session yoga program that participants completed over a 4-month period, with results showing significant improvements (P<.05) on almost all stress-related subjective and physiological variables. Results were comparable with cognitive behavioral therapy.23

Not only has it been shown that yoga helps patients on a psychological level, but a recent study reported that 90-minute sessions of mindfulness meditation and gentle Hatha yoga over an 8-week period led to observable benefits on a cellular level, as telomere length was maintained in distressed breast cancer survivors compared to decreases in telomere length in the control group with patients who solely participated in a stress management seminar.24 To date, there are no known studies examining the effects of yoga on patients with skin cancer. However, a few studies have specifically examined the effect of yoga in managing non–cancer-related dermatologic issues. Specifically, one small study of psoriasis patients found that those who listened to mindfulness meditation tapes while undergoing standard phototherapy (psoralen plus UVA) healed faster than those who underwent phototherapy treatment alone.25

 

 

Because some dermatologic problems have comorbidities and increased risk factors of other medical problems, such as psoriasis with psoriatic arthritis and metabolic diseases (eg, abdominal obesity, diabetes, nonalcoholic fatty liver disease, dyslipidemia, metabolic syndrome, chronic kidney disease), it is even more pertinent to recommend approaches for healthy mind and body well-being as a supplement to medical care.26

Final Thoughts

With accurate diagnosis by a dermatologist, appropriate conventional treatments can improve dermatologic problems. These treatments alone can reduce patients’ stress and improve skin, hair, and nail conditions; however, if it is clear that stress is interfering with a patient’s overall well-being and ability to cope with his/her dermatologic condition, concurrent stress management interventions may be warranted. In some instances, recommending yoga sessions, mindful meditation, or breathing exercises may help, while in others referral to a mental health professional may be necessary.

Beyond the direct physiological effects of stress, it also is worth mentioning that patients who deal with stress also tend to scratch, pick, or irritate their skin more and often lack the motivation to adhere to skin care regimens or treatments, again supporting the idea that our approach in managing these patients must be multifaceted. As dermatologists in training, residents should be cognizant of the potential psychological sequelae of some dermatologic problems and be aware of the possible use of supplemental interventions by our patients.

Regardless of its spiritual origins, yoga has become a popular way of reaching mind and body well-being with nearly 30 million people practicing regularly worldwide.1 Yoga, which is the combination of physical postures, controlled breathing, and meditation or mindfulness, has long been used in complementary and alternative medicine around the world and recently has gained popularity as a therapeutic practice, with nearly 14 million Americans reporting that yoga was recommended to them by a physician or therapist.2,3 Studies suggest that people who participate in even brief yoga programs may see improvements in anxiety, somatic stress and discomfort, health-related quality of life, and self-rated sleep quality, all benefits that can help medical conditions, especially those that are dermatologic in nature.4,5

Stress and Dermatologic Conditions

The interaction between the mind, skin, and body is well known. Research in psychoneuroimmunology, the interaction between psychological processes and the nervous and immune systems, has examined the role of neuropeptides, hormones, and neurotransmitters in psychodermatological disorders. The correlation between neuroimmunological pathways and skin inflammation is now well recognized, specifically the interactions between the brain and skin underlying many dermatological diseases (eg, acne, alopecia areata, various types of eczema and dermatitis, oral and genital herpes, hyperhidrosis, pruritus, psoriasis, rosacea, urticaria, warts, breaking or ridging of the nails).6-9

Two biological systems are known to be affected by the systemic stress response: (1) the hypothalamic-pituitary-adrenal axis, which regulates the release of adrenocorticotropin, ß-endorphin, and cortisol, and (2) the sympathoadrenal medullary system, which regulates the release of catecholamines (eg, epinephrine, norepinephrine).7 Cortisol and catecholamines have been shown to have potent effects on the immune system as well as the inflammatory response.9 Additionally, it has been shown that cutaneous sensory nerve terminals release neuropeptides, including calcitonin gene-related peptide and substance P, both of which have different effects on the local inflammatory response.10,11

Psychological stress is well known to trigger many dermatologic conditions, but it also may lead to abnormal skin barrier function.12 The mechanism in which skin barrier function is affected appears to involve a stress-induced increase of endogenous glucocorticoids, which may consequently disrupt skin barrier function and recovery rates, stratum corneum cohesion, and epidermal antimicrobial function.13,14

Atopic dermatitis, for example, is classified as a psychophysiological disorder. Although it is not caused by stress, atopic dermatitis has been described to be precipitated or exacerbated by stress in patients.15 In fact, it was found that stressful life events preceded the onset of itching in more than 70% of patients with atopic dermatitis,16 which is especially relevant, as there is no cure and patients often experience a lifelong struggle with the condition. Additionally, stress mediates the degranulation of mast cells via corticotropin-releasing hormone and neuropeptides, and the upregulation of mast cell corticotropin-releasing hormone receptors supporting its putative role in the pathogenesis of urticaria.9,17 Furthermore, the increase in cortisol also has been described in the exacerbation of acne during times of stress.18

Psychological factors affect the management of skin conditions in more than one-third of reported dermatology patients; therefore, it is important to consider these factors in the treatment of chronic dermatological conditions, especially when they are inquired by the patient.19,20

Yoga Benefits in the Literature

The therapeutic potential of yoga has been explored in a growing number of randomized controlled trials to date.21 A recently published bibliometric analysis provided a comprehensive review of the characteristics of the randomized yoga trials available in the literature.22 The review included 366 full-text articles, with the 2 earliest studies published in 1975 and nearly 90% published within the last decade. In addition to healthy patients, it was found these randomized controlled yoga trials most commonly enrolled patients with breast cancer, depression, asthma, and type 2 diabetes mellitus.22 Another study examined psychological (eg, self-rated stress and stress behavior, anger, exhaustion, quality of life) and physiological (eg, blood pressure, heart rate, urinary catecholamines, salivary cortisol) measurements obtained before and after a 10-session yoga program that participants completed over a 4-month period, with results showing significant improvements (P<.05) on almost all stress-related subjective and physiological variables. Results were comparable with cognitive behavioral therapy.23

Not only has it been shown that yoga helps patients on a psychological level, but a recent study reported that 90-minute sessions of mindfulness meditation and gentle Hatha yoga over an 8-week period led to observable benefits on a cellular level, as telomere length was maintained in distressed breast cancer survivors compared to decreases in telomere length in the control group with patients who solely participated in a stress management seminar.24 To date, there are no known studies examining the effects of yoga on patients with skin cancer. However, a few studies have specifically examined the effect of yoga in managing non–cancer-related dermatologic issues. Specifically, one small study of psoriasis patients found that those who listened to mindfulness meditation tapes while undergoing standard phototherapy (psoralen plus UVA) healed faster than those who underwent phototherapy treatment alone.25

 

 

Because some dermatologic problems have comorbidities and increased risk factors of other medical problems, such as psoriasis with psoriatic arthritis and metabolic diseases (eg, abdominal obesity, diabetes, nonalcoholic fatty liver disease, dyslipidemia, metabolic syndrome, chronic kidney disease), it is even more pertinent to recommend approaches for healthy mind and body well-being as a supplement to medical care.26

Final Thoughts

With accurate diagnosis by a dermatologist, appropriate conventional treatments can improve dermatologic problems. These treatments alone can reduce patients’ stress and improve skin, hair, and nail conditions; however, if it is clear that stress is interfering with a patient’s overall well-being and ability to cope with his/her dermatologic condition, concurrent stress management interventions may be warranted. In some instances, recommending yoga sessions, mindful meditation, or breathing exercises may help, while in others referral to a mental health professional may be necessary.

Beyond the direct physiological effects of stress, it also is worth mentioning that patients who deal with stress also tend to scratch, pick, or irritate their skin more and often lack the motivation to adhere to skin care regimens or treatments, again supporting the idea that our approach in managing these patients must be multifaceted. As dermatologists in training, residents should be cognizant of the potential psychological sequelae of some dermatologic problems and be aware of the possible use of supplemental interventions by our patients.

References

1. Dangerfield A. Yoga wars. BBC News. http://news.bbc.co.uk/1/hi/7844691.stm. Published January 23, 2009. Accessed March 25, 2015.

2. Yoga Journal releases 2012 yoga in America market study [press release]. San Francisco, CA: Yoga Journal; December 6, 2012.

3. De Michaelis E. A History of Modern Yoga: Patanjali and Western Esotericism. London, United Kingdom: A&C Black; 2005.

4. Telles S, Singh N, Yadav A, et al. Effect of yoga on different aspects of mental health. Indian J Physiol Pharmacol. 2012;56:245-254.

5. Rodriguez-Vallecillo E, Woodbury-Fariña MA. Dermatological manifestations of stress in normal and psychiatric populations. Psychiatr Clin North Am. 2014;37:625-651.

6. Stander S, Raap U, Weisshaar E, et al. Pathogenesis of pruritus. J Dtsch Dermatol Ges. 2011;9:456-463.

7. Arck PC, Slominski A, Theoharides TC, et al. Neuroimmunology of stress: skin takes center stage. J Invest Dermatol. 2006;126:1697-1704.

8. Recognizing the mind-skin connection. Harvard Health Publications Web site. http://www.health.harvard.edu/newsletter_article/Recognizing_the_mind-skin_connection. Published November 1, 2006. Accessed March 31, 2015.

9. Tausk F, Elenkov I, Moynihan J. Psychoneuroimmunology. Dermatol Ther. 2008;21:22-31.

10. Pavlovic S, Liezmann C, Blois SM, et al. Substance P is a key mediator of stress-induced protection from allergic sensitization via modified antigen presentation. J Immunol. 2011;186:848-855.

11. Toyoda M, Nakamura M, Makino T, et al. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol. 2002;147:71-79.

12. Koo JYM, Lee CS. General approach to evaluating psychodermatological disorders. In: Koo JYM, Lee CS, eds. Psychocutaneous Medicine. New York, NY: Marcel Dekker; 2003:1-29.

13. Garg A, Chren MM, Sands LP, et al. Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders. Arch Dermatol. 2001;137:53-59.

14. Elias PM, Sun R, Eder AR, et al. Treating atopic dermatitis at the source: corrective barrier repair therapy based upon new pathogenic insights. Expert Rev Dermatol. 2013;8:27-36.

15. Morren MA, Przybilla B, Bamelis M, et al. Atopic dermatitis: triggering factors. J Am Acad Dermatol. 1994;31:467-473.

16. Faulstich ME, Williamson DA. An overview of atopic dermatitis: toward a bio-behavioural integration. J Psychosom Res. 1985;29:647-654.

17. Theoharides TC, Donelan JM, Papadopoulou N, et al. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25:563-568.

18. Suh DH, Kwon HH. What’s new in the physiopathology of acne [published online ahead of print Jan 24, 2015]? Br J Dermatol. doi:10.1111/bjd.13634.

19. Picardi A, Mazzotti E, Pasquini P. Prevalence and correlates of suicidal ideation among patients with skin disease. J Am Acad Dermatol. 2006;54:420-426.

20. Ponarovsky B, Amital D, Lazarov A, et al. Anxiety and depression in patients with allergic and non-allergic cutaneous disorders. Int J Dermatol. 2011;50:1217-1222.

21. Khalsa SB. Yoga as a therapeutic intervention: a bibliometric analysis of published research studies. Indian J Physiol Pharmacol. 2004;48:269-285.

22. Cramer H, Lauche R, Dobos G. Characteristics of randomized controlled trials of yoga: a bibliometric analysis. BMC Complement Altern Med. 2014;14:328.

23. Granath J, Ingvarsson S, von Thiele U, et al. Stress management: a randomized study of cognitive behavioural therapy and yoga. Cogn Behav Ther. 2006;35:3-10.

24. Carlson LE, Beattie TL, Giese-Davis J, et al. Mindfulness-based cancer recovery and supportive-expressive therapy maintain telomere length relative to controls in distressed breast cancer survivors. Cancer. 2015;121:476-484.

25. Kabat-Zinn J, Wheeler E, Light T, et al. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom Med. 1998;60:625-632.

26. Gisondi P, Galvan A, Idolazzi L, et al. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front Med (Lausanne). 2015;2:1.

References

1. Dangerfield A. Yoga wars. BBC News. http://news.bbc.co.uk/1/hi/7844691.stm. Published January 23, 2009. Accessed March 25, 2015.

2. Yoga Journal releases 2012 yoga in America market study [press release]. San Francisco, CA: Yoga Journal; December 6, 2012.

3. De Michaelis E. A History of Modern Yoga: Patanjali and Western Esotericism. London, United Kingdom: A&C Black; 2005.

4. Telles S, Singh N, Yadav A, et al. Effect of yoga on different aspects of mental health. Indian J Physiol Pharmacol. 2012;56:245-254.

5. Rodriguez-Vallecillo E, Woodbury-Fariña MA. Dermatological manifestations of stress in normal and psychiatric populations. Psychiatr Clin North Am. 2014;37:625-651.

6. Stander S, Raap U, Weisshaar E, et al. Pathogenesis of pruritus. J Dtsch Dermatol Ges. 2011;9:456-463.

7. Arck PC, Slominski A, Theoharides TC, et al. Neuroimmunology of stress: skin takes center stage. J Invest Dermatol. 2006;126:1697-1704.

8. Recognizing the mind-skin connection. Harvard Health Publications Web site. http://www.health.harvard.edu/newsletter_article/Recognizing_the_mind-skin_connection. Published November 1, 2006. Accessed March 31, 2015.

9. Tausk F, Elenkov I, Moynihan J. Psychoneuroimmunology. Dermatol Ther. 2008;21:22-31.

10. Pavlovic S, Liezmann C, Blois SM, et al. Substance P is a key mediator of stress-induced protection from allergic sensitization via modified antigen presentation. J Immunol. 2011;186:848-855.

11. Toyoda M, Nakamura M, Makino T, et al. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol. 2002;147:71-79.

12. Koo JYM, Lee CS. General approach to evaluating psychodermatological disorders. In: Koo JYM, Lee CS, eds. Psychocutaneous Medicine. New York, NY: Marcel Dekker; 2003:1-29.

13. Garg A, Chren MM, Sands LP, et al. Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders. Arch Dermatol. 2001;137:53-59.

14. Elias PM, Sun R, Eder AR, et al. Treating atopic dermatitis at the source: corrective barrier repair therapy based upon new pathogenic insights. Expert Rev Dermatol. 2013;8:27-36.

15. Morren MA, Przybilla B, Bamelis M, et al. Atopic dermatitis: triggering factors. J Am Acad Dermatol. 1994;31:467-473.

16. Faulstich ME, Williamson DA. An overview of atopic dermatitis: toward a bio-behavioural integration. J Psychosom Res. 1985;29:647-654.

17. Theoharides TC, Donelan JM, Papadopoulou N, et al. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25:563-568.

18. Suh DH, Kwon HH. What’s new in the physiopathology of acne [published online ahead of print Jan 24, 2015]? Br J Dermatol. doi:10.1111/bjd.13634.

19. Picardi A, Mazzotti E, Pasquini P. Prevalence and correlates of suicidal ideation among patients with skin disease. J Am Acad Dermatol. 2006;54:420-426.

20. Ponarovsky B, Amital D, Lazarov A, et al. Anxiety and depression in patients with allergic and non-allergic cutaneous disorders. Int J Dermatol. 2011;50:1217-1222.

21. Khalsa SB. Yoga as a therapeutic intervention: a bibliometric analysis of published research studies. Indian J Physiol Pharmacol. 2004;48:269-285.

22. Cramer H, Lauche R, Dobos G. Characteristics of randomized controlled trials of yoga: a bibliometric analysis. BMC Complement Altern Med. 2014;14:328.

23. Granath J, Ingvarsson S, von Thiele U, et al. Stress management: a randomized study of cognitive behavioural therapy and yoga. Cogn Behav Ther. 2006;35:3-10.

24. Carlson LE, Beattie TL, Giese-Davis J, et al. Mindfulness-based cancer recovery and supportive-expressive therapy maintain telomere length relative to controls in distressed breast cancer survivors. Cancer. 2015;121:476-484.

25. Kabat-Zinn J, Wheeler E, Light T, et al. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom Med. 1998;60:625-632.

26. Gisondi P, Galvan A, Idolazzi L, et al. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front Med (Lausanne). 2015;2:1.

Issue
Cutis - 95(4)
Issue
Cutis - 95(4)
Page Number
E23-E25
Page Number
E23-E25
Publications
Publications
Topics
Article Type
Display Headline
Yoga for Dermatologic Conditions
Display Headline
Yoga for Dermatologic Conditions
Legacy Keywords
Yoga, alternative medicine, Dermatologic Conditions,
Legacy Keywords
Yoga, alternative medicine, Dermatologic Conditions,
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

What Is Your Diagnosis? New World Cutaneous Leishmaniasis

Article Type
Changed
Display Headline
What Is Your Diagnosis? New World Cutaneous Leishmaniasis

A 40-year-old man presented with a nonhealing ulcer on the right hand of 2 months’ duration. The lesion had started as a pruritic papule while he was visiting Guyana 2 months prior. The area had slowly enlarged with progressive ulceration. He denied any systemic signs including fever, chills, or weight loss, and his medical history was unremarkable. Physical examination revealed a 4-cm fungating ulceration with heaped-up borders on the dorsal aspect of the right hand.

The Diagnosis: New World Cutaneous Leishmaniasis

In addition to the ulceration on the right hand, a 2-cm ulcerated plaque also had developed on the right side of the chin a few days later (Figure 1). A biopsy was obtained from the lesion on the hand. Histopathologic examination revealed granulomatous inflammation with numerous histiocytes containing intracellular organisms (Figure 2). The microorganisms had pale pink nuclei with basophilic kinetoplasts (Figure 3). Tissue culture showed a mixed growth of gram-positive and gram-negative organisms but no predominant organism. Fungal and mycobacterial cultures were negative. A diagnosis of New World cutaneous leishmaniasis (CL) was made due to visualization of intracellular microorganisms containing basophilic kinetoplasts. Polymerase chain reaction on the tissue block confirmed the presence of Leishmania guyanensis.

Figure 1. A 2-cm ulcerated plaque on the right side of the chin.

Figure 2. Pseudoepitheliomatous hyperplasia overlying a mixed dermal infiltrate of lymphocytes and numerous histiocytes (H&E, original magnification ×40).

Figure 3. Numerous histiocytes containing intracellular organisms. The microorganisms have pale pink nuclei with basophilic kinetoplasts (H&E, original magnification ×200).

Cutaneous leishmaniasis is caused by protozoa from the Leishmania species and is transmitted by the bite of the female sandfly. There are 2 classifications for the disease: Old World and New World. Old World CL is transmitted by the sandfly of the genus Phlebotomus, which is endemic in Asia, Africa, the Mediterranean, and the Middle East. New World CL is transmitted by the sandflies of the genus Lutzomyia, which are endemic in Mexico, Central America, and South America. There have been occasional cases of autochthonous transmission reported in Texas and Oklahoma,1 but there has been no known transmission of CL in Australia or the Pacific Islands.2 Human infection can be transmitted by 21 species of Leishmania and can be speciated by designated laboratories such as the US Centers for Disease Control and Prevention (CDC) and the Walter Reed Army Institute of Research (Silver Spring, Maryland) using tissue culture and polymerase chain reaction.1 The CDC can assist with the collection of specimens and supply of culture medium for cases occurring in the United States. Identification of the species is important because there are associated implications for treatment and prognosis.

There are 3 major forms of leishmaniasis: cutaneous, mucocutaneous, and visceral. Cutaneous leishmaniasis is the most common form. There are approximately 1.5 million new cases of CL each year worldwide,3 and more than 90% of these cases occur in Afghanistan, Algeria, Iran, Iraq, Saudi Arabia, Syria, Brazil, and Peru.1 New World CL is caused by 2 species complexes: Leishmania mexicana and Leishmania viannia, including the subspecies L guyanensis, which was seen in our patient.

Cutaneous leishmaniasis usually begins as a small, well-defined papule at the site of the insect bite that then enlarges and becomes a nodule or plaque. Next, the lesion becomes ulcerated with raised borders (Figure 1). The ulcer typically is painless unless there is secondary bacterial or fungal infection.3,4 The incubation period usually is 2 to 8 weeks and multiple lesions may be present, as seen in our patient.4

Old World CL can resolve without treatment, but New World CL is less likely to spontaneously resolve. Additionally, there is a greater risk for spread of the infection to mucous membranes or for systemic dissemination if New World CL is left untreated.2,5 Patients with multiple lesions (ie, ≥3); large lesions (ie, >2.5 cm); lesions on the face, hands, feet, or joints; and those who are immunocompromised should be treated promptly.2 Pentavalent antimonials (eg, meglumine antimoniate, sodium stibogluconate) are the treatment of choice for New World CL, except for infections caused by L guyanensis. The most common pentavalent antimonial agent used in the United States is sodium stibogluconate and is given at a standard intravenous dose of 20 mg antimony/kg daily for 20 days.2 The drug is only available through the CDC’s Drug Service under an Investigational New Drug protocol.1

Intramuscular pentamidine (3 mg/kg daily every other day for 4 doses) is the first-line treatment of CL caused by L guyanensis because systemic antimony usually is not effective.2,6,7 Intralesional injection with pentavalent antimonials usually is not recommended for treatment of New World CL because of the possibility of disseminated disease.2 Liposomal amphotericin B has mainly been used to treat visceral and mucosal leishmaniasis, but there have been some small studies and case reports that have showed it to be successful in treating CL.8-10 Larger controlled studies need to be performed. Oral antifungal drugs (eg, fluconazole, ketoconazole, itraconazole) also have been used to treat CL with variable results depending on the Leishmania species.11

 

 

There currently are no vaccines or drugs available to prevent against leishmaniasis. Preventive measures such as avoiding outdoor activities from dusk to dawn when sandflies are the most active, wearing protective clothing, and applying insect repellent that contains DEET (diethyltoluamide) can help reduce a traveler’s risk for becoming infected. Mosquito nets also should be treated with permethrin, which acts as an insect repellent, as sandflies are so small that they can penetrate mosquito nets.1,3,11

Acknowledgements—We would like to thank Francis Steurer, MS, and Barbara Herwaldt, MD, MPH, at the CDC in Atlanta, Georgia, for their help with the identification of the Leishmania species.

References

1. Herwaldt BL, Magill AJ. Infectious diseases related to travel: leishmaniasis, cutaneous. Centers for Disease Control and Prevention Web site. http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-5/cutaneous-leish maniasis.htm. Published August 1, 2013. Accessed March 5, 2015.

2. Mitropolos P, Konidas P, Durkin-Konidas M. New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. J Am Acad Dermatol. 2010;63:309-322.

3. Hepburn NC. Cutaneous leishmaniasis: an overview. J Postgrad Med. 2003;49:50-54.

4. Markle WH, Makhoul K. Cutaneous leishmaniasis: recognition and treatment. Am Fam Physician. 2004;69:1455-1460.

5. Couppié P, Clyti E, Sainte Marie D, et al. Disseminated cutaneous leishmaniasis due to Leishmania guyanensis: case of a patient with 425 lesions. Am J Trop Med Hyg. 2004;71:558-560.

6. Nacher M, Carme B, Sainte Marie D, et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol. 2001;95:331-336.

7. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Trav Med Inf Dis. 2007;5:150-158.

8. Solomon M, Baum S, Barzilai A, et al. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol. 2007;56:612-616.

9. Konecny P, Stark DJ. An Australian case of New World cutaneous leishmaniasis. Med J Aust. 2007;186:315-317.

10. Brown M, Noursadeghi M, Boyle J, et al. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol. 2005;153:203-205.

11. Parasites: leishmaniasis. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/parasites/leishmaniasis/index.html. Updated January 10, 2013. Accessed March 5, 2015.

Article PDF
Author and Disclosure Information

Cara Hennings, MD; Karen Bloch, MD, MPH; Jami Miller, MD; Jeffrey Zwerner, MD

From Vanderbilt University, Nashville, Tennessee. Drs. Hennings, Miller, and Zwerner are from the Department of Dermatology, and Dr. Bloch is from the Department of Infectious Disease.

The authors report no conflict of interest.

Correspondence: Jami Miller, MD, Department of Dermatology, Vanderbilt University, 719 Thompson Ln, Ste 26300, Nashville, TN 37204 (jami.miller@vanderbilt.edu).

Issue
Cutis - 95(4)
Publications
Topics
Page Number
208, 229-230
Legacy Keywords
ulcer, nonhealing ulcer, leishmaniasis, leishmania species,
Sections
Author and Disclosure Information

Cara Hennings, MD; Karen Bloch, MD, MPH; Jami Miller, MD; Jeffrey Zwerner, MD

From Vanderbilt University, Nashville, Tennessee. Drs. Hennings, Miller, and Zwerner are from the Department of Dermatology, and Dr. Bloch is from the Department of Infectious Disease.

The authors report no conflict of interest.

Correspondence: Jami Miller, MD, Department of Dermatology, Vanderbilt University, 719 Thompson Ln, Ste 26300, Nashville, TN 37204 (jami.miller@vanderbilt.edu).

Author and Disclosure Information

Cara Hennings, MD; Karen Bloch, MD, MPH; Jami Miller, MD; Jeffrey Zwerner, MD

From Vanderbilt University, Nashville, Tennessee. Drs. Hennings, Miller, and Zwerner are from the Department of Dermatology, and Dr. Bloch is from the Department of Infectious Disease.

The authors report no conflict of interest.

Correspondence: Jami Miller, MD, Department of Dermatology, Vanderbilt University, 719 Thompson Ln, Ste 26300, Nashville, TN 37204 (jami.miller@vanderbilt.edu).

Article PDF
Article PDF
Related Articles

A 40-year-old man presented with a nonhealing ulcer on the right hand of 2 months’ duration. The lesion had started as a pruritic papule while he was visiting Guyana 2 months prior. The area had slowly enlarged with progressive ulceration. He denied any systemic signs including fever, chills, or weight loss, and his medical history was unremarkable. Physical examination revealed a 4-cm fungating ulceration with heaped-up borders on the dorsal aspect of the right hand.

The Diagnosis: New World Cutaneous Leishmaniasis

In addition to the ulceration on the right hand, a 2-cm ulcerated plaque also had developed on the right side of the chin a few days later (Figure 1). A biopsy was obtained from the lesion on the hand. Histopathologic examination revealed granulomatous inflammation with numerous histiocytes containing intracellular organisms (Figure 2). The microorganisms had pale pink nuclei with basophilic kinetoplasts (Figure 3). Tissue culture showed a mixed growth of gram-positive and gram-negative organisms but no predominant organism. Fungal and mycobacterial cultures were negative. A diagnosis of New World cutaneous leishmaniasis (CL) was made due to visualization of intracellular microorganisms containing basophilic kinetoplasts. Polymerase chain reaction on the tissue block confirmed the presence of Leishmania guyanensis.

Figure 1. A 2-cm ulcerated plaque on the right side of the chin.

Figure 2. Pseudoepitheliomatous hyperplasia overlying a mixed dermal infiltrate of lymphocytes and numerous histiocytes (H&E, original magnification ×40).

Figure 3. Numerous histiocytes containing intracellular organisms. The microorganisms have pale pink nuclei with basophilic kinetoplasts (H&E, original magnification ×200).

Cutaneous leishmaniasis is caused by protozoa from the Leishmania species and is transmitted by the bite of the female sandfly. There are 2 classifications for the disease: Old World and New World. Old World CL is transmitted by the sandfly of the genus Phlebotomus, which is endemic in Asia, Africa, the Mediterranean, and the Middle East. New World CL is transmitted by the sandflies of the genus Lutzomyia, which are endemic in Mexico, Central America, and South America. There have been occasional cases of autochthonous transmission reported in Texas and Oklahoma,1 but there has been no known transmission of CL in Australia or the Pacific Islands.2 Human infection can be transmitted by 21 species of Leishmania and can be speciated by designated laboratories such as the US Centers for Disease Control and Prevention (CDC) and the Walter Reed Army Institute of Research (Silver Spring, Maryland) using tissue culture and polymerase chain reaction.1 The CDC can assist with the collection of specimens and supply of culture medium for cases occurring in the United States. Identification of the species is important because there are associated implications for treatment and prognosis.

There are 3 major forms of leishmaniasis: cutaneous, mucocutaneous, and visceral. Cutaneous leishmaniasis is the most common form. There are approximately 1.5 million new cases of CL each year worldwide,3 and more than 90% of these cases occur in Afghanistan, Algeria, Iran, Iraq, Saudi Arabia, Syria, Brazil, and Peru.1 New World CL is caused by 2 species complexes: Leishmania mexicana and Leishmania viannia, including the subspecies L guyanensis, which was seen in our patient.

Cutaneous leishmaniasis usually begins as a small, well-defined papule at the site of the insect bite that then enlarges and becomes a nodule or plaque. Next, the lesion becomes ulcerated with raised borders (Figure 1). The ulcer typically is painless unless there is secondary bacterial or fungal infection.3,4 The incubation period usually is 2 to 8 weeks and multiple lesions may be present, as seen in our patient.4

Old World CL can resolve without treatment, but New World CL is less likely to spontaneously resolve. Additionally, there is a greater risk for spread of the infection to mucous membranes or for systemic dissemination if New World CL is left untreated.2,5 Patients with multiple lesions (ie, ≥3); large lesions (ie, >2.5 cm); lesions on the face, hands, feet, or joints; and those who are immunocompromised should be treated promptly.2 Pentavalent antimonials (eg, meglumine antimoniate, sodium stibogluconate) are the treatment of choice for New World CL, except for infections caused by L guyanensis. The most common pentavalent antimonial agent used in the United States is sodium stibogluconate and is given at a standard intravenous dose of 20 mg antimony/kg daily for 20 days.2 The drug is only available through the CDC’s Drug Service under an Investigational New Drug protocol.1

Intramuscular pentamidine (3 mg/kg daily every other day for 4 doses) is the first-line treatment of CL caused by L guyanensis because systemic antimony usually is not effective.2,6,7 Intralesional injection with pentavalent antimonials usually is not recommended for treatment of New World CL because of the possibility of disseminated disease.2 Liposomal amphotericin B has mainly been used to treat visceral and mucosal leishmaniasis, but there have been some small studies and case reports that have showed it to be successful in treating CL.8-10 Larger controlled studies need to be performed. Oral antifungal drugs (eg, fluconazole, ketoconazole, itraconazole) also have been used to treat CL with variable results depending on the Leishmania species.11

 

 

There currently are no vaccines or drugs available to prevent against leishmaniasis. Preventive measures such as avoiding outdoor activities from dusk to dawn when sandflies are the most active, wearing protective clothing, and applying insect repellent that contains DEET (diethyltoluamide) can help reduce a traveler’s risk for becoming infected. Mosquito nets also should be treated with permethrin, which acts as an insect repellent, as sandflies are so small that they can penetrate mosquito nets.1,3,11

Acknowledgements—We would like to thank Francis Steurer, MS, and Barbara Herwaldt, MD, MPH, at the CDC in Atlanta, Georgia, for their help with the identification of the Leishmania species.

A 40-year-old man presented with a nonhealing ulcer on the right hand of 2 months’ duration. The lesion had started as a pruritic papule while he was visiting Guyana 2 months prior. The area had slowly enlarged with progressive ulceration. He denied any systemic signs including fever, chills, or weight loss, and his medical history was unremarkable. Physical examination revealed a 4-cm fungating ulceration with heaped-up borders on the dorsal aspect of the right hand.

The Diagnosis: New World Cutaneous Leishmaniasis

In addition to the ulceration on the right hand, a 2-cm ulcerated plaque also had developed on the right side of the chin a few days later (Figure 1). A biopsy was obtained from the lesion on the hand. Histopathologic examination revealed granulomatous inflammation with numerous histiocytes containing intracellular organisms (Figure 2). The microorganisms had pale pink nuclei with basophilic kinetoplasts (Figure 3). Tissue culture showed a mixed growth of gram-positive and gram-negative organisms but no predominant organism. Fungal and mycobacterial cultures were negative. A diagnosis of New World cutaneous leishmaniasis (CL) was made due to visualization of intracellular microorganisms containing basophilic kinetoplasts. Polymerase chain reaction on the tissue block confirmed the presence of Leishmania guyanensis.

Figure 1. A 2-cm ulcerated plaque on the right side of the chin.

Figure 2. Pseudoepitheliomatous hyperplasia overlying a mixed dermal infiltrate of lymphocytes and numerous histiocytes (H&E, original magnification ×40).

Figure 3. Numerous histiocytes containing intracellular organisms. The microorganisms have pale pink nuclei with basophilic kinetoplasts (H&E, original magnification ×200).

Cutaneous leishmaniasis is caused by protozoa from the Leishmania species and is transmitted by the bite of the female sandfly. There are 2 classifications for the disease: Old World and New World. Old World CL is transmitted by the sandfly of the genus Phlebotomus, which is endemic in Asia, Africa, the Mediterranean, and the Middle East. New World CL is transmitted by the sandflies of the genus Lutzomyia, which are endemic in Mexico, Central America, and South America. There have been occasional cases of autochthonous transmission reported in Texas and Oklahoma,1 but there has been no known transmission of CL in Australia or the Pacific Islands.2 Human infection can be transmitted by 21 species of Leishmania and can be speciated by designated laboratories such as the US Centers for Disease Control and Prevention (CDC) and the Walter Reed Army Institute of Research (Silver Spring, Maryland) using tissue culture and polymerase chain reaction.1 The CDC can assist with the collection of specimens and supply of culture medium for cases occurring in the United States. Identification of the species is important because there are associated implications for treatment and prognosis.

There are 3 major forms of leishmaniasis: cutaneous, mucocutaneous, and visceral. Cutaneous leishmaniasis is the most common form. There are approximately 1.5 million new cases of CL each year worldwide,3 and more than 90% of these cases occur in Afghanistan, Algeria, Iran, Iraq, Saudi Arabia, Syria, Brazil, and Peru.1 New World CL is caused by 2 species complexes: Leishmania mexicana and Leishmania viannia, including the subspecies L guyanensis, which was seen in our patient.

Cutaneous leishmaniasis usually begins as a small, well-defined papule at the site of the insect bite that then enlarges and becomes a nodule or plaque. Next, the lesion becomes ulcerated with raised borders (Figure 1). The ulcer typically is painless unless there is secondary bacterial or fungal infection.3,4 The incubation period usually is 2 to 8 weeks and multiple lesions may be present, as seen in our patient.4

Old World CL can resolve without treatment, but New World CL is less likely to spontaneously resolve. Additionally, there is a greater risk for spread of the infection to mucous membranes or for systemic dissemination if New World CL is left untreated.2,5 Patients with multiple lesions (ie, ≥3); large lesions (ie, >2.5 cm); lesions on the face, hands, feet, or joints; and those who are immunocompromised should be treated promptly.2 Pentavalent antimonials (eg, meglumine antimoniate, sodium stibogluconate) are the treatment of choice for New World CL, except for infections caused by L guyanensis. The most common pentavalent antimonial agent used in the United States is sodium stibogluconate and is given at a standard intravenous dose of 20 mg antimony/kg daily for 20 days.2 The drug is only available through the CDC’s Drug Service under an Investigational New Drug protocol.1

Intramuscular pentamidine (3 mg/kg daily every other day for 4 doses) is the first-line treatment of CL caused by L guyanensis because systemic antimony usually is not effective.2,6,7 Intralesional injection with pentavalent antimonials usually is not recommended for treatment of New World CL because of the possibility of disseminated disease.2 Liposomal amphotericin B has mainly been used to treat visceral and mucosal leishmaniasis, but there have been some small studies and case reports that have showed it to be successful in treating CL.8-10 Larger controlled studies need to be performed. Oral antifungal drugs (eg, fluconazole, ketoconazole, itraconazole) also have been used to treat CL with variable results depending on the Leishmania species.11

 

 

There currently are no vaccines or drugs available to prevent against leishmaniasis. Preventive measures such as avoiding outdoor activities from dusk to dawn when sandflies are the most active, wearing protective clothing, and applying insect repellent that contains DEET (diethyltoluamide) can help reduce a traveler’s risk for becoming infected. Mosquito nets also should be treated with permethrin, which acts as an insect repellent, as sandflies are so small that they can penetrate mosquito nets.1,3,11

Acknowledgements—We would like to thank Francis Steurer, MS, and Barbara Herwaldt, MD, MPH, at the CDC in Atlanta, Georgia, for their help with the identification of the Leishmania species.

References

1. Herwaldt BL, Magill AJ. Infectious diseases related to travel: leishmaniasis, cutaneous. Centers for Disease Control and Prevention Web site. http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-5/cutaneous-leish maniasis.htm. Published August 1, 2013. Accessed March 5, 2015.

2. Mitropolos P, Konidas P, Durkin-Konidas M. New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. J Am Acad Dermatol. 2010;63:309-322.

3. Hepburn NC. Cutaneous leishmaniasis: an overview. J Postgrad Med. 2003;49:50-54.

4. Markle WH, Makhoul K. Cutaneous leishmaniasis: recognition and treatment. Am Fam Physician. 2004;69:1455-1460.

5. Couppié P, Clyti E, Sainte Marie D, et al. Disseminated cutaneous leishmaniasis due to Leishmania guyanensis: case of a patient with 425 lesions. Am J Trop Med Hyg. 2004;71:558-560.

6. Nacher M, Carme B, Sainte Marie D, et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol. 2001;95:331-336.

7. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Trav Med Inf Dis. 2007;5:150-158.

8. Solomon M, Baum S, Barzilai A, et al. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol. 2007;56:612-616.

9. Konecny P, Stark DJ. An Australian case of New World cutaneous leishmaniasis. Med J Aust. 2007;186:315-317.

10. Brown M, Noursadeghi M, Boyle J, et al. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol. 2005;153:203-205.

11. Parasites: leishmaniasis. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/parasites/leishmaniasis/index.html. Updated January 10, 2013. Accessed March 5, 2015.

References

1. Herwaldt BL, Magill AJ. Infectious diseases related to travel: leishmaniasis, cutaneous. Centers for Disease Control and Prevention Web site. http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-5/cutaneous-leish maniasis.htm. Published August 1, 2013. Accessed March 5, 2015.

2. Mitropolos P, Konidas P, Durkin-Konidas M. New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. J Am Acad Dermatol. 2010;63:309-322.

3. Hepburn NC. Cutaneous leishmaniasis: an overview. J Postgrad Med. 2003;49:50-54.

4. Markle WH, Makhoul K. Cutaneous leishmaniasis: recognition and treatment. Am Fam Physician. 2004;69:1455-1460.

5. Couppié P, Clyti E, Sainte Marie D, et al. Disseminated cutaneous leishmaniasis due to Leishmania guyanensis: case of a patient with 425 lesions. Am J Trop Med Hyg. 2004;71:558-560.

6. Nacher M, Carme B, Sainte Marie D, et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol. 2001;95:331-336.

7. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Trav Med Inf Dis. 2007;5:150-158.

8. Solomon M, Baum S, Barzilai A, et al. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol. 2007;56:612-616.

9. Konecny P, Stark DJ. An Australian case of New World cutaneous leishmaniasis. Med J Aust. 2007;186:315-317.

10. Brown M, Noursadeghi M, Boyle J, et al. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol. 2005;153:203-205.

11. Parasites: leishmaniasis. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/parasites/leishmaniasis/index.html. Updated January 10, 2013. Accessed March 5, 2015.

Issue
Cutis - 95(4)
Issue
Cutis - 95(4)
Page Number
208, 229-230
Page Number
208, 229-230
Publications
Publications
Topics
Article Type
Display Headline
What Is Your Diagnosis? New World Cutaneous Leishmaniasis
Display Headline
What Is Your Diagnosis? New World Cutaneous Leishmaniasis
Legacy Keywords
ulcer, nonhealing ulcer, leishmaniasis, leishmania species,
Legacy Keywords
ulcer, nonhealing ulcer, leishmaniasis, leishmania species,
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Practice Question Answers: Allergic Contact Dermatitis, Part 3

Article Type
Changed
Display Headline
Practice Question Answers: Allergic Contact Dermatitis, Part 3

1. Which of the following is an amide-type anesthetic?

a. benzocaine

b. cocaine

c. lidocaine

d. procaine

e. tetracaine

 

2. A patient is referred for patch testing for suspected allergic contact dermatitis and is found to have positivity to hydrocortisone butyrate. The patient should try to avoid all of the following, except:

a. desonide

b. desoximetasone

c. fluocinolone

d. fluocinonide

e. triamcinolone

 

3. A patient with a documented contact allergy to neomycin sulfate should avoid all of the following medications, except:

a. bacitracin

b. gentamicin

c. kanamycin

d. mupirocin

e. streptomycin

 

4. Imidazolidinyl urea can cross-react with all of the following, except:

a. diazolidinyl urea

b. DMDM hydantoin

c. para-aminobenzoic acid

d. quaternium-15

e. tris(hydroxymethyl)nitromethane

 

5. Mercaptobenzothiazole can coreact with all of the following, except:

a. carbamates

b. dibenzothiazyl disulfide

c. mercapto mix

d. methyldibromo glutaronitrile

 

e. thiurams

Publications
Topics
Sections
Related Articles

1. Which of the following is an amide-type anesthetic?

a. benzocaine

b. cocaine

c. lidocaine

d. procaine

e. tetracaine

 

2. A patient is referred for patch testing for suspected allergic contact dermatitis and is found to have positivity to hydrocortisone butyrate. The patient should try to avoid all of the following, except:

a. desonide

b. desoximetasone

c. fluocinolone

d. fluocinonide

e. triamcinolone

 

3. A patient with a documented contact allergy to neomycin sulfate should avoid all of the following medications, except:

a. bacitracin

b. gentamicin

c. kanamycin

d. mupirocin

e. streptomycin

 

4. Imidazolidinyl urea can cross-react with all of the following, except:

a. diazolidinyl urea

b. DMDM hydantoin

c. para-aminobenzoic acid

d. quaternium-15

e. tris(hydroxymethyl)nitromethane

 

5. Mercaptobenzothiazole can coreact with all of the following, except:

a. carbamates

b. dibenzothiazyl disulfide

c. mercapto mix

d. methyldibromo glutaronitrile

 

e. thiurams

1. Which of the following is an amide-type anesthetic?

a. benzocaine

b. cocaine

c. lidocaine

d. procaine

e. tetracaine

 

2. A patient is referred for patch testing for suspected allergic contact dermatitis and is found to have positivity to hydrocortisone butyrate. The patient should try to avoid all of the following, except:

a. desonide

b. desoximetasone

c. fluocinolone

d. fluocinonide

e. triamcinolone

 

3. A patient with a documented contact allergy to neomycin sulfate should avoid all of the following medications, except:

a. bacitracin

b. gentamicin

c. kanamycin

d. mupirocin

e. streptomycin

 

4. Imidazolidinyl urea can cross-react with all of the following, except:

a. diazolidinyl urea

b. DMDM hydantoin

c. para-aminobenzoic acid

d. quaternium-15

e. tris(hydroxymethyl)nitromethane

 

5. Mercaptobenzothiazole can coreact with all of the following, except:

a. carbamates

b. dibenzothiazyl disulfide

c. mercapto mix

d. methyldibromo glutaronitrile

 

e. thiurams

Publications
Publications
Topics
Article Type
Display Headline
Practice Question Answers: Allergic Contact Dermatitis, Part 3
Display Headline
Practice Question Answers: Allergic Contact Dermatitis, Part 3
Sections
Disallow All Ads
Alternative CME

Allergic Contact Dermatitis, Part 3

Article Type
Changed
Display Headline
Allergic Contact Dermatitis, Part 3
Article PDF
Author and Disclosure Information

 

William W. Huang, MD, MPH

Dr. Huang is Assistant Professor and Associate Program Director of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.

The author reports no conflict of interest.

Publications
Topics
Legacy Keywords
hydrocortisone butyrate, imidazolidinyl urea, iodopropynyl butylcarbamate, lidocaine, mercapto mix, mercaptobenzothiazole, methylchloroisothiazolinone, methyldibromo glutaronitrile, neomycin sulfate, nickel sulfate, allergen of the year, American Contact Dermatitis Society
Sections
Author and Disclosure Information

 

William W. Huang, MD, MPH

Dr. Huang is Assistant Professor and Associate Program Director of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.

The author reports no conflict of interest.

Author and Disclosure Information

 

William W. Huang, MD, MPH

Dr. Huang is Assistant Professor and Associate Program Director of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.

The author reports no conflict of interest.

Article PDF
Article PDF
Related Articles
Publications
Publications
Topics
Article Type
Display Headline
Allergic Contact Dermatitis, Part 3
Display Headline
Allergic Contact Dermatitis, Part 3
Legacy Keywords
hydrocortisone butyrate, imidazolidinyl urea, iodopropynyl butylcarbamate, lidocaine, mercapto mix, mercaptobenzothiazole, methylchloroisothiazolinone, methyldibromo glutaronitrile, neomycin sulfate, nickel sulfate, allergen of the year, American Contact Dermatitis Society
Legacy Keywords
hydrocortisone butyrate, imidazolidinyl urea, iodopropynyl butylcarbamate, lidocaine, mercapto mix, mercaptobenzothiazole, methylchloroisothiazolinone, methyldibromo glutaronitrile, neomycin sulfate, nickel sulfate, allergen of the year, American Contact Dermatitis Society
Sections
Disallow All Ads
Alternative CME
Article PDF Media

What’s Eating You? Cutaneous Larva Migrans

Article Type
Changed
Display Headline
What’s Eating You? Cutaneous Larva Migrans

Cutaneous larva migrans (CLM), also known as creeping eruption, is a pruritic serpiginous eruption caused by the migration of animal hookworm larvae through the epidermis.1,2 The most common parasites are Ancylostoma braziliense (common in dogs and cats) and Ancylostoma caninum (common in dogs).1

Disease Transmission

The infection is typically acquired in warm climates and tropical areas after coming in direct contact with sand or soil that is contaminated with animal feces. Therefore, the eruption most commonly occurs as a single or unilateral erythematous, pruritic, serpiginous tract on the feet, hands, or buttocks (Figure).2 The larval tract typically migrates at a rate of 1 to 2 cm per day,3 which is in contrast to the serpiginous urticarial rash of larva currens of strongyloidiasis that can travel up to 10 cm per hour.4

  
Serpiginous tract of cutaneous larva migrans on the palm (A) and dorsal aspect of the foot (B).

Clinical Presentation

Rarely, CLM can present with bilateral lesions5; in severe cases a single patient can have hundreds of lesions. It also may present as folliculitis and urticarial papules.6 Shih et al7 reported a patient with CLM that presented as a diffuse papular urticarialike eruption following a trip to Thailand. This case may represent an underdiagnosed presentation of CLM. Patients with a history of exposure to contaminated sand or soil diffusely on the body may exhibit lesions in less classic locations, such as the trunk and upper proximal extremities.3

Cutaneous larva migrans is a self-limited eruption, as the larvae cannot complete their lifecycles in the human body and typically die within 2 to 8 weeks.2 However, rare cases lasting up to a year have been reported.3 Sarasombath and Young2 reported a case of CLM that persisted for 4 months with intermittent symptoms characterized by several weeklong intervals with no symptoms or visible rash.

Cutaneous larva migrans typically presents with isolated dermatologic symptoms. Rare cases associated with Löffler syndrome characterized by migratory pulmonary infiltrates and peripheral eosinophilia have been reported.8 Two proposed mechanisms for pulmonary involvement include direct invasion of the lungs by the helminths and a systemic immunologic process triggered by the helminths, resulting in eosinophilic pulmonary infiltration.9

Diagnosis

Cutaneous larva migrans is a clinical diagnosis and skin biopsy usually is not obtained because the larvae often are located 1 to 2 cm beyond the visible erythematous border.3,5 Rarely, the parasites are found on biopsy, revealing larvae that are 0.5-mm thick and up to 10-mm long.10 The larvae typically are confined to the deep epidermis because the parasite lacks the collagenase required to penetrate the basement membrane.2

Langley et al11 showed that confocal scanning laser microscopy can be an effective method for identifying the highly refractile oval larva that disrupt the normal honeycomb pattern of the epidermis. Performing a 4-mm punch biopsy over the identified site can allow for precise excision and treatment of the intact hookworm larvae of CLM. There also are limited reports of dermoscopy being used to facilitate diagnosis of CLM.12 Dermoscopic features of CLM include translucent, brown, structureless areas in a segmental arrangement corresponding to the larval bodies and red-dotted vessels corresponding to an empty burrow.13 However, Zalaudek et al13 concluded that the efficacy of dermoscopy in aiding in the diagnosis of CLM has not been fully established.

Treatment

Cutaneous larva migrans is a self-limited condition that often resolves within 2 to 8 weeks; however, pruritus can be intense and patients therefore are seldom willing to forego treatment. Treatment options include a single oral dose of albendazole 400 mg in adults, with increased efficacy if administered daily for 3 to 5 days (or 10–15 mg/kg, with a maximum dose of 800 mg daily in children), a single oral dose of ivermectin 12 mg in adults (or 150 µg/kg in children), or topical application of thiabendazole 10% to 15% three times daily for at least 15 days.14 Cases of CLM complicated by Löffler syndrome may require a longer treatment course, such as a 7-day course of albendazole 400 mg daily. Tan and Liu9 reported a case of CLM complicated by Löffler syndrome that was successfully treated with albendazole. In this patient, initial treatment with 2 courses of mebendazole (3 days each for a total of 6 days) resulted in improvement of cutaneous lesions but not the pulmonary infiltrate. A subsequent prolonged course of albendazole and intravenous hydrocortisone for 5 days resulted in complete resolution of the pulmonary infiltrate and peripheral eosinophilia. The authors concluded that inadequacy of treatment with mebendazole may be related to differences in the rate of absorption and efficacy when compared to albendazole.9

 

 

Conclusion

Cutaneous larva migrans is a self-limited and pruritic skin eruption that is acquired after direct inoculation with sand or soil that is contaminated with feces containing A braziliense or A caninum. Although the classic presentation is readily identifiable, there are a variety of atypical presentations that may go undiagnosed. Symptomatic relief usually can be achieved with short courses of oral or topical antihelminth medications.

References

1. Berlin JM, Goldberg SJ, McDonough RD, et al. JAAD grand rounds quiz. serpiginous eruption on the leg. J Am Acad Dermatol. 2010;63:921-922.

2. Sarasombath PA, Young PK. An unusual presentation of cutaneous larva migrans. Arch Dermatol. 2007;143:955.

3. Patel S, Aboutalebi S, Vindhya PL, et al. What’s eating you? extensive cutaneous larva migrans (Ancylostoma braziliense). Cutis. 2008;82:239-240.

4. Elston DM, Czarnik K, Brockett R, et al. What’s eating you? Strongyloides stercoralis. Cutis. 2003;71:22-24.

5. Duarte De Sousa ICV, De La Pascua L. Bilateral cutaneous larva migrans [poster reference number 4677]. J Am Acad Dermatol. 2012;66(4, suppl 1):AB106.

6. Caumes E, Ly F, Bricaire F. Cutaneous larva migrans with folliculitis: report of seven cases and review of the literature. Br J Dermatol. 2002;146:314-316.

7. Shih PY, Hsieh MY, Huang YH, et al. Multiple pruritic erythematous papules on the trunk after a trip to Thailand–quiz case. Arch Dermatol. 2010;146:557-562.

8. Wright DO, Gold ED. Löffler’s syndrome associated with creeping eruption (cutaneous helminthiasis): report of twenty-six cases. Arch Intern Med. 1946;78:303-312.

9. Tan SK, Liu TT. Cutaneous larva migrans complicated by Löffler’s syndrome. Arch Dermatol. 2010;146:210-212.

10. Rapini RP, ed. Practical Dermatopathology. Philadelphia, PA: Elsevier; 2005.

11. Langley R, Webb A, Haldane D, et al. Confocal microscopy of cutaneous larva migrans. J Am Acad Dermatol. 2011;64(2, suppl 1):AB100.

12. Aljasser MI, Lui H, Zeng H, et al. Dermoscopy and near-infrared fluorescence imaging of cutaneous larva migrans. Photodermatol Photoimmunol Photomed. 2013;29:337-338.

13. Zalaudek I, Giacomel J, Cabo H, et al. Entodermoscopy: a new tool for diagnosing skin infections and infestations. Dermatology. 2008;216:14-23.

14. Caumes E. Treatment of cutaneous larva migrans. Clin Infect Dis. 2000;30:811-814.

Article PDF
Author and Disclosure Information

Kyle A. Prickett, MD; Tammie C. Ferringer, MD

From the Department of Dermatology, Geisinger Medical Center, Danville, Pennsylvania. Dr. Ferringer also is from the Department of Laboratory Medicine.

The authors report no conflict of interest.

Correspondence: Kyle A. Prickett, MD, 115 Woodbine Ln, Danville, PA 17822-5206 (kaprickett@geisinger.edu).

Issue
Cutis - 95(3)
Publications
Topics
Page Number
126-128
Legacy Keywords
helminth, cutaneous larva migrans, cat hookworm, dog hookworm, Loffler syndrome, confocal scanning laser microscopy
Sections
Author and Disclosure Information

Kyle A. Prickett, MD; Tammie C. Ferringer, MD

From the Department of Dermatology, Geisinger Medical Center, Danville, Pennsylvania. Dr. Ferringer also is from the Department of Laboratory Medicine.

The authors report no conflict of interest.

Correspondence: Kyle A. Prickett, MD, 115 Woodbine Ln, Danville, PA 17822-5206 (kaprickett@geisinger.edu).

Author and Disclosure Information

Kyle A. Prickett, MD; Tammie C. Ferringer, MD

From the Department of Dermatology, Geisinger Medical Center, Danville, Pennsylvania. Dr. Ferringer also is from the Department of Laboratory Medicine.

The authors report no conflict of interest.

Correspondence: Kyle A. Prickett, MD, 115 Woodbine Ln, Danville, PA 17822-5206 (kaprickett@geisinger.edu).

Article PDF
Article PDF
Related Articles

Cutaneous larva migrans (CLM), also known as creeping eruption, is a pruritic serpiginous eruption caused by the migration of animal hookworm larvae through the epidermis.1,2 The most common parasites are Ancylostoma braziliense (common in dogs and cats) and Ancylostoma caninum (common in dogs).1

Disease Transmission

The infection is typically acquired in warm climates and tropical areas after coming in direct contact with sand or soil that is contaminated with animal feces. Therefore, the eruption most commonly occurs as a single or unilateral erythematous, pruritic, serpiginous tract on the feet, hands, or buttocks (Figure).2 The larval tract typically migrates at a rate of 1 to 2 cm per day,3 which is in contrast to the serpiginous urticarial rash of larva currens of strongyloidiasis that can travel up to 10 cm per hour.4

  
Serpiginous tract of cutaneous larva migrans on the palm (A) and dorsal aspect of the foot (B).

Clinical Presentation

Rarely, CLM can present with bilateral lesions5; in severe cases a single patient can have hundreds of lesions. It also may present as folliculitis and urticarial papules.6 Shih et al7 reported a patient with CLM that presented as a diffuse papular urticarialike eruption following a trip to Thailand. This case may represent an underdiagnosed presentation of CLM. Patients with a history of exposure to contaminated sand or soil diffusely on the body may exhibit lesions in less classic locations, such as the trunk and upper proximal extremities.3

Cutaneous larva migrans is a self-limited eruption, as the larvae cannot complete their lifecycles in the human body and typically die within 2 to 8 weeks.2 However, rare cases lasting up to a year have been reported.3 Sarasombath and Young2 reported a case of CLM that persisted for 4 months with intermittent symptoms characterized by several weeklong intervals with no symptoms or visible rash.

Cutaneous larva migrans typically presents with isolated dermatologic symptoms. Rare cases associated with Löffler syndrome characterized by migratory pulmonary infiltrates and peripheral eosinophilia have been reported.8 Two proposed mechanisms for pulmonary involvement include direct invasion of the lungs by the helminths and a systemic immunologic process triggered by the helminths, resulting in eosinophilic pulmonary infiltration.9

Diagnosis

Cutaneous larva migrans is a clinical diagnosis and skin biopsy usually is not obtained because the larvae often are located 1 to 2 cm beyond the visible erythematous border.3,5 Rarely, the parasites are found on biopsy, revealing larvae that are 0.5-mm thick and up to 10-mm long.10 The larvae typically are confined to the deep epidermis because the parasite lacks the collagenase required to penetrate the basement membrane.2

Langley et al11 showed that confocal scanning laser microscopy can be an effective method for identifying the highly refractile oval larva that disrupt the normal honeycomb pattern of the epidermis. Performing a 4-mm punch biopsy over the identified site can allow for precise excision and treatment of the intact hookworm larvae of CLM. There also are limited reports of dermoscopy being used to facilitate diagnosis of CLM.12 Dermoscopic features of CLM include translucent, brown, structureless areas in a segmental arrangement corresponding to the larval bodies and red-dotted vessels corresponding to an empty burrow.13 However, Zalaudek et al13 concluded that the efficacy of dermoscopy in aiding in the diagnosis of CLM has not been fully established.

Treatment

Cutaneous larva migrans is a self-limited condition that often resolves within 2 to 8 weeks; however, pruritus can be intense and patients therefore are seldom willing to forego treatment. Treatment options include a single oral dose of albendazole 400 mg in adults, with increased efficacy if administered daily for 3 to 5 days (or 10–15 mg/kg, with a maximum dose of 800 mg daily in children), a single oral dose of ivermectin 12 mg in adults (or 150 µg/kg in children), or topical application of thiabendazole 10% to 15% three times daily for at least 15 days.14 Cases of CLM complicated by Löffler syndrome may require a longer treatment course, such as a 7-day course of albendazole 400 mg daily. Tan and Liu9 reported a case of CLM complicated by Löffler syndrome that was successfully treated with albendazole. In this patient, initial treatment with 2 courses of mebendazole (3 days each for a total of 6 days) resulted in improvement of cutaneous lesions but not the pulmonary infiltrate. A subsequent prolonged course of albendazole and intravenous hydrocortisone for 5 days resulted in complete resolution of the pulmonary infiltrate and peripheral eosinophilia. The authors concluded that inadequacy of treatment with mebendazole may be related to differences in the rate of absorption and efficacy when compared to albendazole.9

 

 

Conclusion

Cutaneous larva migrans is a self-limited and pruritic skin eruption that is acquired after direct inoculation with sand or soil that is contaminated with feces containing A braziliense or A caninum. Although the classic presentation is readily identifiable, there are a variety of atypical presentations that may go undiagnosed. Symptomatic relief usually can be achieved with short courses of oral or topical antihelminth medications.

Cutaneous larva migrans (CLM), also known as creeping eruption, is a pruritic serpiginous eruption caused by the migration of animal hookworm larvae through the epidermis.1,2 The most common parasites are Ancylostoma braziliense (common in dogs and cats) and Ancylostoma caninum (common in dogs).1

Disease Transmission

The infection is typically acquired in warm climates and tropical areas after coming in direct contact with sand or soil that is contaminated with animal feces. Therefore, the eruption most commonly occurs as a single or unilateral erythematous, pruritic, serpiginous tract on the feet, hands, or buttocks (Figure).2 The larval tract typically migrates at a rate of 1 to 2 cm per day,3 which is in contrast to the serpiginous urticarial rash of larva currens of strongyloidiasis that can travel up to 10 cm per hour.4

  
Serpiginous tract of cutaneous larva migrans on the palm (A) and dorsal aspect of the foot (B).

Clinical Presentation

Rarely, CLM can present with bilateral lesions5; in severe cases a single patient can have hundreds of lesions. It also may present as folliculitis and urticarial papules.6 Shih et al7 reported a patient with CLM that presented as a diffuse papular urticarialike eruption following a trip to Thailand. This case may represent an underdiagnosed presentation of CLM. Patients with a history of exposure to contaminated sand or soil diffusely on the body may exhibit lesions in less classic locations, such as the trunk and upper proximal extremities.3

Cutaneous larva migrans is a self-limited eruption, as the larvae cannot complete their lifecycles in the human body and typically die within 2 to 8 weeks.2 However, rare cases lasting up to a year have been reported.3 Sarasombath and Young2 reported a case of CLM that persisted for 4 months with intermittent symptoms characterized by several weeklong intervals with no symptoms or visible rash.

Cutaneous larva migrans typically presents with isolated dermatologic symptoms. Rare cases associated with Löffler syndrome characterized by migratory pulmonary infiltrates and peripheral eosinophilia have been reported.8 Two proposed mechanisms for pulmonary involvement include direct invasion of the lungs by the helminths and a systemic immunologic process triggered by the helminths, resulting in eosinophilic pulmonary infiltration.9

Diagnosis

Cutaneous larva migrans is a clinical diagnosis and skin biopsy usually is not obtained because the larvae often are located 1 to 2 cm beyond the visible erythematous border.3,5 Rarely, the parasites are found on biopsy, revealing larvae that are 0.5-mm thick and up to 10-mm long.10 The larvae typically are confined to the deep epidermis because the parasite lacks the collagenase required to penetrate the basement membrane.2

Langley et al11 showed that confocal scanning laser microscopy can be an effective method for identifying the highly refractile oval larva that disrupt the normal honeycomb pattern of the epidermis. Performing a 4-mm punch biopsy over the identified site can allow for precise excision and treatment of the intact hookworm larvae of CLM. There also are limited reports of dermoscopy being used to facilitate diagnosis of CLM.12 Dermoscopic features of CLM include translucent, brown, structureless areas in a segmental arrangement corresponding to the larval bodies and red-dotted vessels corresponding to an empty burrow.13 However, Zalaudek et al13 concluded that the efficacy of dermoscopy in aiding in the diagnosis of CLM has not been fully established.

Treatment

Cutaneous larva migrans is a self-limited condition that often resolves within 2 to 8 weeks; however, pruritus can be intense and patients therefore are seldom willing to forego treatment. Treatment options include a single oral dose of albendazole 400 mg in adults, with increased efficacy if administered daily for 3 to 5 days (or 10–15 mg/kg, with a maximum dose of 800 mg daily in children), a single oral dose of ivermectin 12 mg in adults (or 150 µg/kg in children), or topical application of thiabendazole 10% to 15% three times daily for at least 15 days.14 Cases of CLM complicated by Löffler syndrome may require a longer treatment course, such as a 7-day course of albendazole 400 mg daily. Tan and Liu9 reported a case of CLM complicated by Löffler syndrome that was successfully treated with albendazole. In this patient, initial treatment with 2 courses of mebendazole (3 days each for a total of 6 days) resulted in improvement of cutaneous lesions but not the pulmonary infiltrate. A subsequent prolonged course of albendazole and intravenous hydrocortisone for 5 days resulted in complete resolution of the pulmonary infiltrate and peripheral eosinophilia. The authors concluded that inadequacy of treatment with mebendazole may be related to differences in the rate of absorption and efficacy when compared to albendazole.9

 

 

Conclusion

Cutaneous larva migrans is a self-limited and pruritic skin eruption that is acquired after direct inoculation with sand or soil that is contaminated with feces containing A braziliense or A caninum. Although the classic presentation is readily identifiable, there are a variety of atypical presentations that may go undiagnosed. Symptomatic relief usually can be achieved with short courses of oral or topical antihelminth medications.

References

1. Berlin JM, Goldberg SJ, McDonough RD, et al. JAAD grand rounds quiz. serpiginous eruption on the leg. J Am Acad Dermatol. 2010;63:921-922.

2. Sarasombath PA, Young PK. An unusual presentation of cutaneous larva migrans. Arch Dermatol. 2007;143:955.

3. Patel S, Aboutalebi S, Vindhya PL, et al. What’s eating you? extensive cutaneous larva migrans (Ancylostoma braziliense). Cutis. 2008;82:239-240.

4. Elston DM, Czarnik K, Brockett R, et al. What’s eating you? Strongyloides stercoralis. Cutis. 2003;71:22-24.

5. Duarte De Sousa ICV, De La Pascua L. Bilateral cutaneous larva migrans [poster reference number 4677]. J Am Acad Dermatol. 2012;66(4, suppl 1):AB106.

6. Caumes E, Ly F, Bricaire F. Cutaneous larva migrans with folliculitis: report of seven cases and review of the literature. Br J Dermatol. 2002;146:314-316.

7. Shih PY, Hsieh MY, Huang YH, et al. Multiple pruritic erythematous papules on the trunk after a trip to Thailand–quiz case. Arch Dermatol. 2010;146:557-562.

8. Wright DO, Gold ED. Löffler’s syndrome associated with creeping eruption (cutaneous helminthiasis): report of twenty-six cases. Arch Intern Med. 1946;78:303-312.

9. Tan SK, Liu TT. Cutaneous larva migrans complicated by Löffler’s syndrome. Arch Dermatol. 2010;146:210-212.

10. Rapini RP, ed. Practical Dermatopathology. Philadelphia, PA: Elsevier; 2005.

11. Langley R, Webb A, Haldane D, et al. Confocal microscopy of cutaneous larva migrans. J Am Acad Dermatol. 2011;64(2, suppl 1):AB100.

12. Aljasser MI, Lui H, Zeng H, et al. Dermoscopy and near-infrared fluorescence imaging of cutaneous larva migrans. Photodermatol Photoimmunol Photomed. 2013;29:337-338.

13. Zalaudek I, Giacomel J, Cabo H, et al. Entodermoscopy: a new tool for diagnosing skin infections and infestations. Dermatology. 2008;216:14-23.

14. Caumes E. Treatment of cutaneous larva migrans. Clin Infect Dis. 2000;30:811-814.

References

1. Berlin JM, Goldberg SJ, McDonough RD, et al. JAAD grand rounds quiz. serpiginous eruption on the leg. J Am Acad Dermatol. 2010;63:921-922.

2. Sarasombath PA, Young PK. An unusual presentation of cutaneous larva migrans. Arch Dermatol. 2007;143:955.

3. Patel S, Aboutalebi S, Vindhya PL, et al. What’s eating you? extensive cutaneous larva migrans (Ancylostoma braziliense). Cutis. 2008;82:239-240.

4. Elston DM, Czarnik K, Brockett R, et al. What’s eating you? Strongyloides stercoralis. Cutis. 2003;71:22-24.

5. Duarte De Sousa ICV, De La Pascua L. Bilateral cutaneous larva migrans [poster reference number 4677]. J Am Acad Dermatol. 2012;66(4, suppl 1):AB106.

6. Caumes E, Ly F, Bricaire F. Cutaneous larva migrans with folliculitis: report of seven cases and review of the literature. Br J Dermatol. 2002;146:314-316.

7. Shih PY, Hsieh MY, Huang YH, et al. Multiple pruritic erythematous papules on the trunk after a trip to Thailand–quiz case. Arch Dermatol. 2010;146:557-562.

8. Wright DO, Gold ED. Löffler’s syndrome associated with creeping eruption (cutaneous helminthiasis): report of twenty-six cases. Arch Intern Med. 1946;78:303-312.

9. Tan SK, Liu TT. Cutaneous larva migrans complicated by Löffler’s syndrome. Arch Dermatol. 2010;146:210-212.

10. Rapini RP, ed. Practical Dermatopathology. Philadelphia, PA: Elsevier; 2005.

11. Langley R, Webb A, Haldane D, et al. Confocal microscopy of cutaneous larva migrans. J Am Acad Dermatol. 2011;64(2, suppl 1):AB100.

12. Aljasser MI, Lui H, Zeng H, et al. Dermoscopy and near-infrared fluorescence imaging of cutaneous larva migrans. Photodermatol Photoimmunol Photomed. 2013;29:337-338.

13. Zalaudek I, Giacomel J, Cabo H, et al. Entodermoscopy: a new tool for diagnosing skin infections and infestations. Dermatology. 2008;216:14-23.

14. Caumes E. Treatment of cutaneous larva migrans. Clin Infect Dis. 2000;30:811-814.

Issue
Cutis - 95(3)
Issue
Cutis - 95(3)
Page Number
126-128
Page Number
126-128
Publications
Publications
Topics
Article Type
Display Headline
What’s Eating You? Cutaneous Larva Migrans
Display Headline
What’s Eating You? Cutaneous Larva Migrans
Legacy Keywords
helminth, cutaneous larva migrans, cat hookworm, dog hookworm, Loffler syndrome, confocal scanning laser microscopy
Legacy Keywords
helminth, cutaneous larva migrans, cat hookworm, dog hookworm, Loffler syndrome, confocal scanning laser microscopy
Sections
Article Source

PURLs Copyright

Inside the Article

     Practice Points

  • Classic cutaneous larva migrans (CLM) presents with a unilateral, serpiginous, pruritic eruption on the hands, feet, or buttocks following direct contact with sand or soil that is contaminated with Ancylostoma braziliense or Ancylostoma caninum.
  • Atypical presentations of CLM include bilateral distribution; folliculitis and urticarial plaques; prolonged cases lasting up to 1 year; and Löffler syndrome characterized by migratory pulmonary infiltrates and peripheral eosinophilia.
  • Cutaneous larva migrans is self-limited, but treatment often is necessary due to intense pruritus. Treatment options include a single oral dose of albendazole or ivermectin, topical thiabendazole, and prolonged courses of oral albendazole in cases complicated by Löffler syndrome.
Article PDF Media

Inability to Grow Long Hair: A Presentation of Trichorrhexis Nodosa

Article Type
Changed
Display Headline
Inability to Grow Long Hair: A Presentation of Trichorrhexis Nodosa

To the Editor:

First identified by Samuel Wilks in 1852, trichorrhexis nodosa (TN) is a congenital or acquired hair shaft disorder that is characterized by fragile and easily broken hair.1 Congenital TN is rare and can occur in syndromes such as pseudomonilethrix, Netherton syndrome, pili annulati,2 argininosuccinic aciduria,3 trichothiodystrophy,4 Menkes syndrome,5 and trichohepatoenteric syndrome.6 The primary congenital form of TN is inherited as an autosomal-dominant trait in some families. Acquired TN is the most common hair shaft abnormality and often is overlooked. It is provoked by hair injury, usually mechanical or physical, or chemical trauma.7,8

Chemical trauma is caused by the use of permanent hair liquids or dyes. Mechanical injuries are the result of frequent brushing, scalp massage, or lengthy backcombing, and physical damage includes excessive UV exposure or repeated application of heat. Habit tics, trichotillomania, and the scratching and pulling associated with pruritic dermatoses also can result in sufficient damage to provoke TN. Furthermore, this acquired disorder may develop from malnutrition, particularly iron deficiency, or endocrinopathy such as hypothyroidism.9 Seasonal recurrence of TN has been reported from the cumulative effect of repeated soaking in salt water and exposure to UV light. Macroscopically, hair shafts affected by TN contain small white nodes at irregular intervals throughout the length of the hair shaft. These nodes represent areas of cuticular cell disruption, which allows the underlying cortical fibers to separate and fray and gives the node the microscopic appearance of 2 brooms or paintbrushes thrusting together end-to-end by the bristles. The classic description is known as paintbrush fracture.10 Generally, complete breakage occurs at these nodes.

A 21-year-old white woman presented to our clinic with hair fragility and inability to grow long hair of 2 years’ duration. The hair was lusterless and dry. Dermoscopic examination revealed broken blunt-ended hair of uneven length with minute pinpoint grayish white nodules (Figure 1). Small fragments could be easily broken off with gentle tugging on the distal ends. She reported a history of severe sunlight and seawater exposure during the last 2 summers and the continuous use of a flat iron in the last year. Microscopic examination of hair samples with a scanning electron microscope showed the characteristic paintbrush fracture (Figure 2). She had no history of diseases, and blood examinations including complete blood cell count, thyroid function test, and iron levels were within reference range.

Figure 1. Dermoscopy revealed broken blunt-ended hair of uneven length with minute pinpoint grayish white nodules (original magnification ×30).

Figure 2. Scanning electron microscopy showed characteristic paintbrush fracture of the hair shaft (original magnification ×748).

We hypothesize that the seasonal damage caused by exposure to UV light and salt water with repeated trauma from the heat of the flat iron caused distal TN. The patient was given an explanation about the diagnosis of TN and was instructed to avoid the practices that were suspected causes of the condition. Use of a gentle shampoo and conditioner also was recommended. At 6-month follow-up, we noticed an improvement of the quality of hair with a reduction in the whitish nodules and a revival of hair growth.

Acquired TN has been classified into 3 clinical forms: proximal, distal, and localized.1 Proximal TN is common in black individuals who use caustic chemicals when styling the hair. The involved hairs develop the characteristic nodes that break within a few centimeters from the scalp, especially in areas subject to friction from combing or sleeping. Distal TN primarily occurs in white or Asian individuals. In this disorder, nodes and breakage occur near the ends of the hairs that appear dull, dry, and uneven. Breakage commonly is associated with trichoptilosis, or longitudinal splitting, commonly referred to as split ends. This breakage may reflect frequent use of shampoo or heat treatments. The distal acquired form may simulate dandruff or pediculosis and the detection of this hair defect often is casual.

Localized TN, described by Raymond Sabouraud in 1921, is a rare disorder. It occurs in a patch that is usually a few centimeters long. It generally is accompanied by a pruritic dermatosis, such as circumscribed neurodermatitis, contact dermatitis, or atopic dermatitis. Scratching and rubbing most likely are the ultimate causes.

Trichorrhexis nodosa can spontaneously resolve. In all cases, diagnosis depends on careful microscopy examination and, if possible, scanning electron microscopy. Treatment is aimed at minimizing mechanical and physical injury, and chemical trauma. Excessive brushing, hot-combing, permanent waving, and other harsh hair treatments should be avoided. If the hair is long and the damage is distal, it may be sufficient to cut the distal fraction and to change cosmetic practices to prevent relapse.

 

 

Dermatologists who see patients with hair fragility and inability to grow long hair should consider the diagnosis of TN. Acquired TN often is reversible. Complete resolution may take 2 to 4 years depending on the growth of new anagen hairs. All patients with a history of white flecking on the scalp, abnormal fragility of the hair, and failure to attain normal hair length should be questioned about their routine hair care habits as well as environmental or chemical exposures to determine and remove the source of physical or chemical trauma.

References

1. Whiting DA. Structural abnormalities of hair shaft. J Am Acad Dermatol. 1987;16(1, pt 1):1-25.

2. Leider M. Multiple simultaneous anomalies of the hair; report of a case exhibiting trichorrhexis nodosa, pili annulati and trichostasis spinulosa. AMA Arch Derm Syphilol. 1950;62:510-514.

3. Allan JD, Cusworth DC, Dent CE, et al. A disease, probably hereditary characterised by severe mental deficiency and a constant gross abnormality of aminoacid metabolism. Lancet. 1958;1:182-187.

4. Liang C, Morris A, Schlücker S, et al. Structural and molecular hair abnormalities in trichothiodystrophy [published online ahead of print May 25, 2006]. J Invest Dermatol. 2006;126:2210-2216.

5. Taylor CJ, Green SH. Menkes’ syndrome (trichopoliodystrophy): use of scanning electron-microscope in diagnosis and carrier identification. Dev Med Child Neurol. 1981;23:361-368.

6. Hartley JL, Zachos NC, Dawood B, et al. Mutations in TTC37 cause trichohepatoenteric syndrome (phenotypic diarrhea of infancy)[published online ahead of print February 20, 2010]. Gastroenterology. 2010;138:2388-2398.

7. Chernosky ME, Owens DW. Trichorrhexis nodosa. clinical and investigative studies. Arch Dermatol. 1966;94:577-585.

8. Owens DW, Chernosky ME. Trichorrhexis nodosa; in vitro reproduction. Arch Dermatol. 1966;94:586-588.

9. Lurie R, Hodak E, Ginzburg A, et al. Trichorrhexis nodosa: a manifestation of hypothyroidism. Cutis. 1996;57:358-359.

10. Miyamoto M, Tsuboi R, Oh-I T. Case of acquired trichorrhexis nodosa: scanning electron microscopic observation. J Dermatol. 2009;36:109-110.

Article PDF
Author and Disclosure Information

Teresa Sisto, MD; Carolina Bussoletti, MD; Alessandra D’Amore, MD; Nino Favoriti, MD; Luca Fania, MD; Leonardo Celleno, MD

From the Department of Dermatology, Catholic University of the Sacred Heart, Rome, Italy.

The authors report no conflict of interest.

Correspondence: Luca Fania, MD, Department of Dermatology, Catholic University of the Sacred Heart, Largo Gemelli 8, 00168 Rome, Italy (fanluca05@hotmail.it).

Issue
Cutis - 95(3)
Publications
Topics
Page Number
E15-E16
Legacy Keywords
trichorrhexis nodosa, hair shaft disoders, paint brush fracture
Sections
Author and Disclosure Information

Teresa Sisto, MD; Carolina Bussoletti, MD; Alessandra D’Amore, MD; Nino Favoriti, MD; Luca Fania, MD; Leonardo Celleno, MD

From the Department of Dermatology, Catholic University of the Sacred Heart, Rome, Italy.

The authors report no conflict of interest.

Correspondence: Luca Fania, MD, Department of Dermatology, Catholic University of the Sacred Heart, Largo Gemelli 8, 00168 Rome, Italy (fanluca05@hotmail.it).

Author and Disclosure Information

Teresa Sisto, MD; Carolina Bussoletti, MD; Alessandra D’Amore, MD; Nino Favoriti, MD; Luca Fania, MD; Leonardo Celleno, MD

From the Department of Dermatology, Catholic University of the Sacred Heart, Rome, Italy.

The authors report no conflict of interest.

Correspondence: Luca Fania, MD, Department of Dermatology, Catholic University of the Sacred Heart, Largo Gemelli 8, 00168 Rome, Italy (fanluca05@hotmail.it).

Article PDF
Article PDF
Related Articles

To the Editor:

First identified by Samuel Wilks in 1852, trichorrhexis nodosa (TN) is a congenital or acquired hair shaft disorder that is characterized by fragile and easily broken hair.1 Congenital TN is rare and can occur in syndromes such as pseudomonilethrix, Netherton syndrome, pili annulati,2 argininosuccinic aciduria,3 trichothiodystrophy,4 Menkes syndrome,5 and trichohepatoenteric syndrome.6 The primary congenital form of TN is inherited as an autosomal-dominant trait in some families. Acquired TN is the most common hair shaft abnormality and often is overlooked. It is provoked by hair injury, usually mechanical or physical, or chemical trauma.7,8

Chemical trauma is caused by the use of permanent hair liquids or dyes. Mechanical injuries are the result of frequent brushing, scalp massage, or lengthy backcombing, and physical damage includes excessive UV exposure or repeated application of heat. Habit tics, trichotillomania, and the scratching and pulling associated with pruritic dermatoses also can result in sufficient damage to provoke TN. Furthermore, this acquired disorder may develop from malnutrition, particularly iron deficiency, or endocrinopathy such as hypothyroidism.9 Seasonal recurrence of TN has been reported from the cumulative effect of repeated soaking in salt water and exposure to UV light. Macroscopically, hair shafts affected by TN contain small white nodes at irregular intervals throughout the length of the hair shaft. These nodes represent areas of cuticular cell disruption, which allows the underlying cortical fibers to separate and fray and gives the node the microscopic appearance of 2 brooms or paintbrushes thrusting together end-to-end by the bristles. The classic description is known as paintbrush fracture.10 Generally, complete breakage occurs at these nodes.

A 21-year-old white woman presented to our clinic with hair fragility and inability to grow long hair of 2 years’ duration. The hair was lusterless and dry. Dermoscopic examination revealed broken blunt-ended hair of uneven length with minute pinpoint grayish white nodules (Figure 1). Small fragments could be easily broken off with gentle tugging on the distal ends. She reported a history of severe sunlight and seawater exposure during the last 2 summers and the continuous use of a flat iron in the last year. Microscopic examination of hair samples with a scanning electron microscope showed the characteristic paintbrush fracture (Figure 2). She had no history of diseases, and blood examinations including complete blood cell count, thyroid function test, and iron levels were within reference range.

Figure 1. Dermoscopy revealed broken blunt-ended hair of uneven length with minute pinpoint grayish white nodules (original magnification ×30).

Figure 2. Scanning electron microscopy showed characteristic paintbrush fracture of the hair shaft (original magnification ×748).

We hypothesize that the seasonal damage caused by exposure to UV light and salt water with repeated trauma from the heat of the flat iron caused distal TN. The patient was given an explanation about the diagnosis of TN and was instructed to avoid the practices that were suspected causes of the condition. Use of a gentle shampoo and conditioner also was recommended. At 6-month follow-up, we noticed an improvement of the quality of hair with a reduction in the whitish nodules and a revival of hair growth.

Acquired TN has been classified into 3 clinical forms: proximal, distal, and localized.1 Proximal TN is common in black individuals who use caustic chemicals when styling the hair. The involved hairs develop the characteristic nodes that break within a few centimeters from the scalp, especially in areas subject to friction from combing or sleeping. Distal TN primarily occurs in white or Asian individuals. In this disorder, nodes and breakage occur near the ends of the hairs that appear dull, dry, and uneven. Breakage commonly is associated with trichoptilosis, or longitudinal splitting, commonly referred to as split ends. This breakage may reflect frequent use of shampoo or heat treatments. The distal acquired form may simulate dandruff or pediculosis and the detection of this hair defect often is casual.

Localized TN, described by Raymond Sabouraud in 1921, is a rare disorder. It occurs in a patch that is usually a few centimeters long. It generally is accompanied by a pruritic dermatosis, such as circumscribed neurodermatitis, contact dermatitis, or atopic dermatitis. Scratching and rubbing most likely are the ultimate causes.

Trichorrhexis nodosa can spontaneously resolve. In all cases, diagnosis depends on careful microscopy examination and, if possible, scanning electron microscopy. Treatment is aimed at minimizing mechanical and physical injury, and chemical trauma. Excessive brushing, hot-combing, permanent waving, and other harsh hair treatments should be avoided. If the hair is long and the damage is distal, it may be sufficient to cut the distal fraction and to change cosmetic practices to prevent relapse.

 

 

Dermatologists who see patients with hair fragility and inability to grow long hair should consider the diagnosis of TN. Acquired TN often is reversible. Complete resolution may take 2 to 4 years depending on the growth of new anagen hairs. All patients with a history of white flecking on the scalp, abnormal fragility of the hair, and failure to attain normal hair length should be questioned about their routine hair care habits as well as environmental or chemical exposures to determine and remove the source of physical or chemical trauma.

To the Editor:

First identified by Samuel Wilks in 1852, trichorrhexis nodosa (TN) is a congenital or acquired hair shaft disorder that is characterized by fragile and easily broken hair.1 Congenital TN is rare and can occur in syndromes such as pseudomonilethrix, Netherton syndrome, pili annulati,2 argininosuccinic aciduria,3 trichothiodystrophy,4 Menkes syndrome,5 and trichohepatoenteric syndrome.6 The primary congenital form of TN is inherited as an autosomal-dominant trait in some families. Acquired TN is the most common hair shaft abnormality and often is overlooked. It is provoked by hair injury, usually mechanical or physical, or chemical trauma.7,8

Chemical trauma is caused by the use of permanent hair liquids or dyes. Mechanical injuries are the result of frequent brushing, scalp massage, or lengthy backcombing, and physical damage includes excessive UV exposure or repeated application of heat. Habit tics, trichotillomania, and the scratching and pulling associated with pruritic dermatoses also can result in sufficient damage to provoke TN. Furthermore, this acquired disorder may develop from malnutrition, particularly iron deficiency, or endocrinopathy such as hypothyroidism.9 Seasonal recurrence of TN has been reported from the cumulative effect of repeated soaking in salt water and exposure to UV light. Macroscopically, hair shafts affected by TN contain small white nodes at irregular intervals throughout the length of the hair shaft. These nodes represent areas of cuticular cell disruption, which allows the underlying cortical fibers to separate and fray and gives the node the microscopic appearance of 2 brooms or paintbrushes thrusting together end-to-end by the bristles. The classic description is known as paintbrush fracture.10 Generally, complete breakage occurs at these nodes.

A 21-year-old white woman presented to our clinic with hair fragility and inability to grow long hair of 2 years’ duration. The hair was lusterless and dry. Dermoscopic examination revealed broken blunt-ended hair of uneven length with minute pinpoint grayish white nodules (Figure 1). Small fragments could be easily broken off with gentle tugging on the distal ends. She reported a history of severe sunlight and seawater exposure during the last 2 summers and the continuous use of a flat iron in the last year. Microscopic examination of hair samples with a scanning electron microscope showed the characteristic paintbrush fracture (Figure 2). She had no history of diseases, and blood examinations including complete blood cell count, thyroid function test, and iron levels were within reference range.

Figure 1. Dermoscopy revealed broken blunt-ended hair of uneven length with minute pinpoint grayish white nodules (original magnification ×30).

Figure 2. Scanning electron microscopy showed characteristic paintbrush fracture of the hair shaft (original magnification ×748).

We hypothesize that the seasonal damage caused by exposure to UV light and salt water with repeated trauma from the heat of the flat iron caused distal TN. The patient was given an explanation about the diagnosis of TN and was instructed to avoid the practices that were suspected causes of the condition. Use of a gentle shampoo and conditioner also was recommended. At 6-month follow-up, we noticed an improvement of the quality of hair with a reduction in the whitish nodules and a revival of hair growth.

Acquired TN has been classified into 3 clinical forms: proximal, distal, and localized.1 Proximal TN is common in black individuals who use caustic chemicals when styling the hair. The involved hairs develop the characteristic nodes that break within a few centimeters from the scalp, especially in areas subject to friction from combing or sleeping. Distal TN primarily occurs in white or Asian individuals. In this disorder, nodes and breakage occur near the ends of the hairs that appear dull, dry, and uneven. Breakage commonly is associated with trichoptilosis, or longitudinal splitting, commonly referred to as split ends. This breakage may reflect frequent use of shampoo or heat treatments. The distal acquired form may simulate dandruff or pediculosis and the detection of this hair defect often is casual.

Localized TN, described by Raymond Sabouraud in 1921, is a rare disorder. It occurs in a patch that is usually a few centimeters long. It generally is accompanied by a pruritic dermatosis, such as circumscribed neurodermatitis, contact dermatitis, or atopic dermatitis. Scratching and rubbing most likely are the ultimate causes.

Trichorrhexis nodosa can spontaneously resolve. In all cases, diagnosis depends on careful microscopy examination and, if possible, scanning electron microscopy. Treatment is aimed at minimizing mechanical and physical injury, and chemical trauma. Excessive brushing, hot-combing, permanent waving, and other harsh hair treatments should be avoided. If the hair is long and the damage is distal, it may be sufficient to cut the distal fraction and to change cosmetic practices to prevent relapse.

 

 

Dermatologists who see patients with hair fragility and inability to grow long hair should consider the diagnosis of TN. Acquired TN often is reversible. Complete resolution may take 2 to 4 years depending on the growth of new anagen hairs. All patients with a history of white flecking on the scalp, abnormal fragility of the hair, and failure to attain normal hair length should be questioned about their routine hair care habits as well as environmental or chemical exposures to determine and remove the source of physical or chemical trauma.

References

1. Whiting DA. Structural abnormalities of hair shaft. J Am Acad Dermatol. 1987;16(1, pt 1):1-25.

2. Leider M. Multiple simultaneous anomalies of the hair; report of a case exhibiting trichorrhexis nodosa, pili annulati and trichostasis spinulosa. AMA Arch Derm Syphilol. 1950;62:510-514.

3. Allan JD, Cusworth DC, Dent CE, et al. A disease, probably hereditary characterised by severe mental deficiency and a constant gross abnormality of aminoacid metabolism. Lancet. 1958;1:182-187.

4. Liang C, Morris A, Schlücker S, et al. Structural and molecular hair abnormalities in trichothiodystrophy [published online ahead of print May 25, 2006]. J Invest Dermatol. 2006;126:2210-2216.

5. Taylor CJ, Green SH. Menkes’ syndrome (trichopoliodystrophy): use of scanning electron-microscope in diagnosis and carrier identification. Dev Med Child Neurol. 1981;23:361-368.

6. Hartley JL, Zachos NC, Dawood B, et al. Mutations in TTC37 cause trichohepatoenteric syndrome (phenotypic diarrhea of infancy)[published online ahead of print February 20, 2010]. Gastroenterology. 2010;138:2388-2398.

7. Chernosky ME, Owens DW. Trichorrhexis nodosa. clinical and investigative studies. Arch Dermatol. 1966;94:577-585.

8. Owens DW, Chernosky ME. Trichorrhexis nodosa; in vitro reproduction. Arch Dermatol. 1966;94:586-588.

9. Lurie R, Hodak E, Ginzburg A, et al. Trichorrhexis nodosa: a manifestation of hypothyroidism. Cutis. 1996;57:358-359.

10. Miyamoto M, Tsuboi R, Oh-I T. Case of acquired trichorrhexis nodosa: scanning electron microscopic observation. J Dermatol. 2009;36:109-110.

References

1. Whiting DA. Structural abnormalities of hair shaft. J Am Acad Dermatol. 1987;16(1, pt 1):1-25.

2. Leider M. Multiple simultaneous anomalies of the hair; report of a case exhibiting trichorrhexis nodosa, pili annulati and trichostasis spinulosa. AMA Arch Derm Syphilol. 1950;62:510-514.

3. Allan JD, Cusworth DC, Dent CE, et al. A disease, probably hereditary characterised by severe mental deficiency and a constant gross abnormality of aminoacid metabolism. Lancet. 1958;1:182-187.

4. Liang C, Morris A, Schlücker S, et al. Structural and molecular hair abnormalities in trichothiodystrophy [published online ahead of print May 25, 2006]. J Invest Dermatol. 2006;126:2210-2216.

5. Taylor CJ, Green SH. Menkes’ syndrome (trichopoliodystrophy): use of scanning electron-microscope in diagnosis and carrier identification. Dev Med Child Neurol. 1981;23:361-368.

6. Hartley JL, Zachos NC, Dawood B, et al. Mutations in TTC37 cause trichohepatoenteric syndrome (phenotypic diarrhea of infancy)[published online ahead of print February 20, 2010]. Gastroenterology. 2010;138:2388-2398.

7. Chernosky ME, Owens DW. Trichorrhexis nodosa. clinical and investigative studies. Arch Dermatol. 1966;94:577-585.

8. Owens DW, Chernosky ME. Trichorrhexis nodosa; in vitro reproduction. Arch Dermatol. 1966;94:586-588.

9. Lurie R, Hodak E, Ginzburg A, et al. Trichorrhexis nodosa: a manifestation of hypothyroidism. Cutis. 1996;57:358-359.

10. Miyamoto M, Tsuboi R, Oh-I T. Case of acquired trichorrhexis nodosa: scanning electron microscopic observation. J Dermatol. 2009;36:109-110.

Issue
Cutis - 95(3)
Issue
Cutis - 95(3)
Page Number
E15-E16
Page Number
E15-E16
Publications
Publications
Topics
Article Type
Display Headline
Inability to Grow Long Hair: A Presentation of Trichorrhexis Nodosa
Display Headline
Inability to Grow Long Hair: A Presentation of Trichorrhexis Nodosa
Legacy Keywords
trichorrhexis nodosa, hair shaft disoders, paint brush fracture
Legacy Keywords
trichorrhexis nodosa, hair shaft disoders, paint brush fracture
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Dermatologic Toxicity in a Patient Receiving Liposomal Doxorubicin

Article Type
Changed
Display Headline
Dermatologic Toxicity in a Patient Receiving Liposomal Doxorubicin

To the Editor:

Liposomal doxorubicin hydrochloride is an anthracycline topoisomerase inhibitor indicated for ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma.1 It also has been used with limited success in a clinical trial of previously treated patients with endometrial cancer.2 The most common adverse reactions include asthenia, fatigue, fever, anorexia, nausea, vomiting, stomatitis, diarrhea, constipation, hand-and-foot syndrome, rash, neutropenia, thrombocytopenia, and anemia.1

A 58-year-old woman with a history of stage IIIA endometrial cancer underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy soon after diagnosis. She then completed 5 high-dose-rate brachytherapy treatments and 6 cycles of paclitaxel and carboplatin. Follow-up imaging revealed pulmonary metastasis. The patient was then enrolled in a clinical trial but was switched to 40 mg/m2 liposomal doxorubicin given once every 28 days for 5 cycles after progression of disease.

After each dose of doxorubicin, she developed redness of the palms and soles. Following the third cycle of doxorubicin, a painful rash involving the thighs and axilla appeared with some desquamation in the left axilla. Three weeks after the fourth dose of doxorubicin, she presented with severe worsening of the rash to involve the extensor elbows (Figure 1), back, and lower legs with bilateral axillary desquamation. The bilateral medial thighs were erythematous with maceration that was tender and blanchable (Figure 2). The total affected body surface area was 10% to 15%. There was no involvement of the mucosa. She was treated with hydrogel sheet dressings and silver sulfadiazine cream 1%.

Figure 1. Extensor surface of the elbow with an erythematous patch 3 weeks after the fourth dose of doxorubicin.
Figure 2. Medial thigh with erythema and maceration.

The patient’s rash was thought to be due to doxorubicin toxicity; however, a 4-mm punch biopsy specimen from the left thigh was taken for culture and hemotoxylin and eosin stain to rule out other possibilities. Biopsy was consistent with a drug reaction, revealing superficial perivascular dermatitis with keratinocyte atypia of the epidermis. Doxorubicin was discontinued and the rash resolved completely within 2 weeks, except for some thickening of the skin on the palms, soles, and thighs. After a delay of approximately 1 week, doxorubicin was resumed at a lower dose of 30 mg/m2. No dermatologic symptoms followed treatment at this dose.

Four clinical patterns of doxorubicin toxicity are recognized. The most common pattern is acral erythema, also known as hand-and-foot syndrome, which is followed by desquamation of the palms and soles, occurring in approximately 50% of patients. Ten percent of patients experience a diffuse follicular rash with mild, diffuse, scaly erythema and follicular accentuation that often occurs over the lateral limbs but also may occur over the trunk. New melanotic macules may appear on the trunk or extremities including palms and soles.3 Finally, an intertrigolike eruption exacerbated by friction with erythematous patches over skin folds or in areas of friction also has been described.3-5 Our patient presented with a combination of dermatologic toxicities including acral erythema and intertrigolike eruption. Acral erythema occurred in 24 of 60 patients and intertrigolike eruption occurred in 5 of 60 patients in one study.3 Another report documented both occurring together.5

Treatment of doxorubicin skin toxicity consists of reduction of the dose of doxorubicin, supportive care, and patient education. Specific treatments include topical wound care, emollient creams, and pain management with analgesics. Other interventions include wearing loose clothing, avoiding vigorous exercise, and sitting on padded surfaces.6

Doxorubicin skin toxicity presents in several clinical patterns. Although acral erythema is the most common pattern, severe intertrigolike eruptions similar to our case may occur. Physicians caring for patients receiving doxorubicin should be aware of the variety of presentations of skin toxicity and the possible need for dose reduction to decrease symptoms.

References

1. Doxil [package insert]. Horsham, PA: Janssen Products, LP; 2014.

2. Muggia FM, Blessing JA, Sorosky J, et al. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2002;20:2360-2364.

3. Lotem M, Hubert A, Lyass O, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol. 2000;136:1475-1480.

4. Korver GE, Ronald H, Petersen MJ. An intertrigo-like eruption from pegylated liposomal doxorubicin. J Drugs Dermatol. 2006;5:901-902.

5. Sánchez Henarejos P, Ros Martinez S, Marín Zafra GR,
et al. Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD). Clin Transl Oncol. 2009;11:486-487.

6. von Moos R, Thuerlimann BJ, Aapro M, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts [published online ahead of print March 10, 2008]. Eur J Cancer. 2008;44:781-790.

Article PDF
Author and Disclosure Information

Kristen N. Richards, MD; Rebecca L. Stone, MD; Rashid M. Rashid, MD, PhD; Susan Y. Chon, MD

Drs. Richards, Rashid, and Chon are from the Department of Dermatology and Dr. Stone is from the Department of Gynecologic Oncology, all at the MD Anderson Cancer Center, Houston.

The authors report no conflict of interest.

Correspondence: Susan Y. Chon, MD, MD Anderson Cancer Center, Department of Dermatology, 515 Holcombe Blvd, Unit 1452, Houston, TX 77030 (SusanChon@mdanderson.org).

Issue
Cutis - 95(2)
Publications
Topics
Page Number
E10-E11
Legacy Keywords
doxorubicin, acral erythema, hand-foot syndrome, intertrigolike eruption
Sections
Author and Disclosure Information

Kristen N. Richards, MD; Rebecca L. Stone, MD; Rashid M. Rashid, MD, PhD; Susan Y. Chon, MD

Drs. Richards, Rashid, and Chon are from the Department of Dermatology and Dr. Stone is from the Department of Gynecologic Oncology, all at the MD Anderson Cancer Center, Houston.

The authors report no conflict of interest.

Correspondence: Susan Y. Chon, MD, MD Anderson Cancer Center, Department of Dermatology, 515 Holcombe Blvd, Unit 1452, Houston, TX 77030 (SusanChon@mdanderson.org).

Author and Disclosure Information

Kristen N. Richards, MD; Rebecca L. Stone, MD; Rashid M. Rashid, MD, PhD; Susan Y. Chon, MD

Drs. Richards, Rashid, and Chon are from the Department of Dermatology and Dr. Stone is from the Department of Gynecologic Oncology, all at the MD Anderson Cancer Center, Houston.

The authors report no conflict of interest.

Correspondence: Susan Y. Chon, MD, MD Anderson Cancer Center, Department of Dermatology, 515 Holcombe Blvd, Unit 1452, Houston, TX 77030 (SusanChon@mdanderson.org).

Article PDF
Article PDF
Related Articles

To the Editor:

Liposomal doxorubicin hydrochloride is an anthracycline topoisomerase inhibitor indicated for ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma.1 It also has been used with limited success in a clinical trial of previously treated patients with endometrial cancer.2 The most common adverse reactions include asthenia, fatigue, fever, anorexia, nausea, vomiting, stomatitis, diarrhea, constipation, hand-and-foot syndrome, rash, neutropenia, thrombocytopenia, and anemia.1

A 58-year-old woman with a history of stage IIIA endometrial cancer underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy soon after diagnosis. She then completed 5 high-dose-rate brachytherapy treatments and 6 cycles of paclitaxel and carboplatin. Follow-up imaging revealed pulmonary metastasis. The patient was then enrolled in a clinical trial but was switched to 40 mg/m2 liposomal doxorubicin given once every 28 days for 5 cycles after progression of disease.

After each dose of doxorubicin, she developed redness of the palms and soles. Following the third cycle of doxorubicin, a painful rash involving the thighs and axilla appeared with some desquamation in the left axilla. Three weeks after the fourth dose of doxorubicin, she presented with severe worsening of the rash to involve the extensor elbows (Figure 1), back, and lower legs with bilateral axillary desquamation. The bilateral medial thighs were erythematous with maceration that was tender and blanchable (Figure 2). The total affected body surface area was 10% to 15%. There was no involvement of the mucosa. She was treated with hydrogel sheet dressings and silver sulfadiazine cream 1%.

Figure 1. Extensor surface of the elbow with an erythematous patch 3 weeks after the fourth dose of doxorubicin.
Figure 2. Medial thigh with erythema and maceration.

The patient’s rash was thought to be due to doxorubicin toxicity; however, a 4-mm punch biopsy specimen from the left thigh was taken for culture and hemotoxylin and eosin stain to rule out other possibilities. Biopsy was consistent with a drug reaction, revealing superficial perivascular dermatitis with keratinocyte atypia of the epidermis. Doxorubicin was discontinued and the rash resolved completely within 2 weeks, except for some thickening of the skin on the palms, soles, and thighs. After a delay of approximately 1 week, doxorubicin was resumed at a lower dose of 30 mg/m2. No dermatologic symptoms followed treatment at this dose.

Four clinical patterns of doxorubicin toxicity are recognized. The most common pattern is acral erythema, also known as hand-and-foot syndrome, which is followed by desquamation of the palms and soles, occurring in approximately 50% of patients. Ten percent of patients experience a diffuse follicular rash with mild, diffuse, scaly erythema and follicular accentuation that often occurs over the lateral limbs but also may occur over the trunk. New melanotic macules may appear on the trunk or extremities including palms and soles.3 Finally, an intertrigolike eruption exacerbated by friction with erythematous patches over skin folds or in areas of friction also has been described.3-5 Our patient presented with a combination of dermatologic toxicities including acral erythema and intertrigolike eruption. Acral erythema occurred in 24 of 60 patients and intertrigolike eruption occurred in 5 of 60 patients in one study.3 Another report documented both occurring together.5

Treatment of doxorubicin skin toxicity consists of reduction of the dose of doxorubicin, supportive care, and patient education. Specific treatments include topical wound care, emollient creams, and pain management with analgesics. Other interventions include wearing loose clothing, avoiding vigorous exercise, and sitting on padded surfaces.6

Doxorubicin skin toxicity presents in several clinical patterns. Although acral erythema is the most common pattern, severe intertrigolike eruptions similar to our case may occur. Physicians caring for patients receiving doxorubicin should be aware of the variety of presentations of skin toxicity and the possible need for dose reduction to decrease symptoms.

To the Editor:

Liposomal doxorubicin hydrochloride is an anthracycline topoisomerase inhibitor indicated for ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma.1 It also has been used with limited success in a clinical trial of previously treated patients with endometrial cancer.2 The most common adverse reactions include asthenia, fatigue, fever, anorexia, nausea, vomiting, stomatitis, diarrhea, constipation, hand-and-foot syndrome, rash, neutropenia, thrombocytopenia, and anemia.1

A 58-year-old woman with a history of stage IIIA endometrial cancer underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy soon after diagnosis. She then completed 5 high-dose-rate brachytherapy treatments and 6 cycles of paclitaxel and carboplatin. Follow-up imaging revealed pulmonary metastasis. The patient was then enrolled in a clinical trial but was switched to 40 mg/m2 liposomal doxorubicin given once every 28 days for 5 cycles after progression of disease.

After each dose of doxorubicin, she developed redness of the palms and soles. Following the third cycle of doxorubicin, a painful rash involving the thighs and axilla appeared with some desquamation in the left axilla. Three weeks after the fourth dose of doxorubicin, she presented with severe worsening of the rash to involve the extensor elbows (Figure 1), back, and lower legs with bilateral axillary desquamation. The bilateral medial thighs were erythematous with maceration that was tender and blanchable (Figure 2). The total affected body surface area was 10% to 15%. There was no involvement of the mucosa. She was treated with hydrogel sheet dressings and silver sulfadiazine cream 1%.

Figure 1. Extensor surface of the elbow with an erythematous patch 3 weeks after the fourth dose of doxorubicin.
Figure 2. Medial thigh with erythema and maceration.

The patient’s rash was thought to be due to doxorubicin toxicity; however, a 4-mm punch biopsy specimen from the left thigh was taken for culture and hemotoxylin and eosin stain to rule out other possibilities. Biopsy was consistent with a drug reaction, revealing superficial perivascular dermatitis with keratinocyte atypia of the epidermis. Doxorubicin was discontinued and the rash resolved completely within 2 weeks, except for some thickening of the skin on the palms, soles, and thighs. After a delay of approximately 1 week, doxorubicin was resumed at a lower dose of 30 mg/m2. No dermatologic symptoms followed treatment at this dose.

Four clinical patterns of doxorubicin toxicity are recognized. The most common pattern is acral erythema, also known as hand-and-foot syndrome, which is followed by desquamation of the palms and soles, occurring in approximately 50% of patients. Ten percent of patients experience a diffuse follicular rash with mild, diffuse, scaly erythema and follicular accentuation that often occurs over the lateral limbs but also may occur over the trunk. New melanotic macules may appear on the trunk or extremities including palms and soles.3 Finally, an intertrigolike eruption exacerbated by friction with erythematous patches over skin folds or in areas of friction also has been described.3-5 Our patient presented with a combination of dermatologic toxicities including acral erythema and intertrigolike eruption. Acral erythema occurred in 24 of 60 patients and intertrigolike eruption occurred in 5 of 60 patients in one study.3 Another report documented both occurring together.5

Treatment of doxorubicin skin toxicity consists of reduction of the dose of doxorubicin, supportive care, and patient education. Specific treatments include topical wound care, emollient creams, and pain management with analgesics. Other interventions include wearing loose clothing, avoiding vigorous exercise, and sitting on padded surfaces.6

Doxorubicin skin toxicity presents in several clinical patterns. Although acral erythema is the most common pattern, severe intertrigolike eruptions similar to our case may occur. Physicians caring for patients receiving doxorubicin should be aware of the variety of presentations of skin toxicity and the possible need for dose reduction to decrease symptoms.

References

1. Doxil [package insert]. Horsham, PA: Janssen Products, LP; 2014.

2. Muggia FM, Blessing JA, Sorosky J, et al. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2002;20:2360-2364.

3. Lotem M, Hubert A, Lyass O, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol. 2000;136:1475-1480.

4. Korver GE, Ronald H, Petersen MJ. An intertrigo-like eruption from pegylated liposomal doxorubicin. J Drugs Dermatol. 2006;5:901-902.

5. Sánchez Henarejos P, Ros Martinez S, Marín Zafra GR,
et al. Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD). Clin Transl Oncol. 2009;11:486-487.

6. von Moos R, Thuerlimann BJ, Aapro M, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts [published online ahead of print March 10, 2008]. Eur J Cancer. 2008;44:781-790.

References

1. Doxil [package insert]. Horsham, PA: Janssen Products, LP; 2014.

2. Muggia FM, Blessing JA, Sorosky J, et al. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2002;20:2360-2364.

3. Lotem M, Hubert A, Lyass O, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol. 2000;136:1475-1480.

4. Korver GE, Ronald H, Petersen MJ. An intertrigo-like eruption from pegylated liposomal doxorubicin. J Drugs Dermatol. 2006;5:901-902.

5. Sánchez Henarejos P, Ros Martinez S, Marín Zafra GR,
et al. Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD). Clin Transl Oncol. 2009;11:486-487.

6. von Moos R, Thuerlimann BJ, Aapro M, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts [published online ahead of print March 10, 2008]. Eur J Cancer. 2008;44:781-790.

Issue
Cutis - 95(2)
Issue
Cutis - 95(2)
Page Number
E10-E11
Page Number
E10-E11
Publications
Publications
Topics
Article Type
Display Headline
Dermatologic Toxicity in a Patient Receiving Liposomal Doxorubicin
Display Headline
Dermatologic Toxicity in a Patient Receiving Liposomal Doxorubicin
Legacy Keywords
doxorubicin, acral erythema, hand-foot syndrome, intertrigolike eruption
Legacy Keywords
doxorubicin, acral erythema, hand-foot syndrome, intertrigolike eruption
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Cold Panniculitis: Delayed Onset in an Adult

Article Type
Changed
Display Headline
Cold Panniculitis: Delayed Onset in an Adult

The panniculitides can be a complex dermatologic entity for both dermatologists and dermatopathologists. The history, clinical examination, and histology need to be correlated to arrive at a differential diagnosis that will ultimately provide a diagnosis for the subcutaneous lesions. Panniculitis is an inflammation of the subcutaneous adipose tissue and can be associated with systemic diseases. According to Peters and Su,1 “Anatomic location of lesions, presence or absence of ulceration, occurrence of lipoatrophy, history of trauma, association with immunologic or metabolic disorders, and age of the patient are important clinical data to consider in conjunction with the microscopic features.” The panniculitides histologic differences may be subtle because they all include septal and lobular components, but one is usually more dominant in leading to a diagnosis along with the clinical findings.2

Cold panniculitis is a form of traumatic panniculitis. We present a unique case of this condition that was caused by use of a cold therapy unit following surgery to relieve pain.

Case Report

A 37-year-old woman presented for a routine postoperative visit 15 days following arthroscopic repair of a superior labrum anterior posterior tear in the left shoulder with a single suture anchor. The patient reported a rash that had developed 10 days postoperatively on the left upper arm. The rash started as red dots that progressively became larger, painful, and warm to the touch. The rash did not spread anywhere else on the patient’s body, and she denied fever, chills, and pruritus. She had tried using diphenhydramine without relief. The only new medication the patient had started prior to the eruption was oxycodone, which was initiated immediately following surgery. Prior to surgery, the entire left upper extremity including the shoulder had been prepared with a preoperative surgical skin antiseptic. There were no visible signs of the antiseptic on the skin at the time of presentation. The patient reported that she had applied a cold therapy unit to the left upper arm over her clothing for 1 hour every night since surgery. The cold therapy unit frequently is used to help decrease postoperative pain, swelling, inflammation, and narcotic use following surgical procedures.

Physical examination revealed multiple well-defined, erythematous, tender, indurated, warm nodules on the lateral aspect of the left upper arm (Figure 1). No other areas of eruption were noted on the body, and there was no swelling of the left elbow, forearm, wrist, or hand. The left upper extremity demonstrated intact sensation, rapid capillary refill, and a palpable radial pulse. Her weight was 230.1 lb with a body mass index of 35.

 

Figure 1. Multiple well-defined, erythematous, tender, indurated nodules presented on the lateral aspect of the left upper arm.

Figure 2. Punch biopsy showed a superficial and deep perivascular and periadnexal lymphoid infiltrate with involvement of the subcutis (H&E, original magnification ×40).

A 5-mm punch biopsy from a nodule on the left upper arm was performed, and pathology demonstrated vacuolar interface changes with patchy parakeratosis, spongiosis, and dyskeratosis on staining with hematoxylin and eosin. Pandermal and subcutaneous perivascular, periadnexal, and mild interstitial lymphohistiocytic infiltrate with occasional neutrophils and eosinophils were noted (Figure 2). The inflammation extended to the subcutaneous fat involving both septae and lobules with a primarily lobular distribution.

Clinical and pathologic correlation was required to arrive at a definitive diagnosis of cold panniculitis. The epidermal and dermal changes were consistent with a pernio or chilblains type of insult, and the septal and lobular panniculitis was indicative of cold panniculitis. The patient was advised to discontinue use of the cold therapy device as well as any other form of icing of the left shoulder or arm. She continued the oxycodone for pain control. Four weeks postoperatively, only desquamation remained where the nodules had previously appeared, which also eventually resolved.

Comment

Infants and small children are more predisposed to cold panniculitis than adults. In their 2008 review, Quesada-Cortés et al3 found the first report of cold panniculitis by Hochsinger in 1902 in a German pediatric journal, followed by reports from Lemez in 1928 and Haxthausen in 1941, which subsequently described similar cases in infants. Adult cases were not reported until 1963 by Solomon and Beerman4 and then in 1980 by Beacham et al.5

Etiologies for children have included popsicles, ice packs applied to the face to control supraventricular tachycardia or to the lower extremities after vaccinations, and cold weather exposure.6 The chemical composition of fat tissue plays a role in pediatric patients. According to Quesada-Cortés et al,3 subcutaneous fat in newborns is rich in saturated oils such as palmitic and stearic acids that have a higher solidification point. A small decrease in an infant’s temperature may result in crystallization of fat. The subcutaneous fat tends to become more unsaturated with aging with more oleic acid, and the solidification temperature diminishes.7

 

 

Cryoglobulins and cold agglutinins have not been demonstrated to be a cause of cold panniculitis in infants.7 Severe cold exposure or predisposition to certain conditions such as cryofibrinogenemia may occur in some adult patients. Gender does not seem to be a factor in children; however, in adults, women tend to be more predisposed to cold panniculitis secondary to obesity and participation in activities such as cycling, motorcycling, or horseback riding in cold conditions.3

On clinical examination, cold panniculitis features erythematous, firm, tender nodules on the cheeks and chin in infants and small children.2 These areas often are exposed to cold weather or wind because they typically are not covered with protective clothing.3 Nodules generally occur 1 to 3 days following exposure to cold and usually resolve spontaneously within 2 weeks.8 Popsicle panniculitis is characterized by a reddish discoloration on both cheeks 1 or 2 days after sucking on popsicles or ice cubes. This reaction can be reproduced in a half day by applying an ice cube to the volar forearm for 2 minutes, which can help diagnose and differentiate this subset of cold panniuculits.3 The red area in cold panniculitis eventually turns purple, becomes less indurated, and fades in approximately 3 months, but occasionally residual hyperpigmentation will last for a few months. Ice packs used as treatment of congenital cardiac arrhythmias in some cardiac surgeries and as surface cooling for management of birth asphyxia can produce a similar physical presentation.3

Equestrian panniculitis is characterized by erythematous, violaceous, tender plaques on the upper lateral thighs of young females who participate in horseback riding in the winter while wearing tight-fitting pants.2,5 These plaques typically occur within several hours and over the next week become painful, violaceous, and indurated or develop red nodules or plaques that can ulcerate or become crusted.3 These lesions usually will spontaneously resolve within 3 weeks, but new areas may occur again during the winter on further exposure with occasional persistent hyperpigmentation. These areas usually disappear at the end of winter with warmer weather or when horseback riding is discontinued. Perniosis also needs to be considered in the differential diagnosis due to the location and appearance of the lesions.3

It is important to obtain the correct specimen for biopsy. According to Peters and Su,1 a deep excisional biopsy that includes multiple fat lobules in addition to dermis and epidermis is critical. On histology, cold panniculitis usually demonstrates a primarily lobular inflammation. There typically is a superficial and deep perivascular lymphocytic infiltrate in the papillary dermis with edema noted in the connective tissue around the eccrine glands that can appear similar to perniosis on histopathology.9 Deposition of mucin, focal panniculitis surrounded by fatty tissue without inflammatory changes within the same field, and fat necrosis with pseudocysts and numerous lipophages also are characteristic features of cold panniculitis.10 Needlelike clefts are not present in cold panniculitis but appear in subcutaneous fat necrosis of the newborn.1

Different treatments have been tried, but no substantial impact on the rate of dissipation of the lesions has been noted. The plaques slowly resolve without scarring over 2 to 3 weeks if the cold source is removed.2 Application of a heating pad to the affected area has been used with limited success. Vasodilators such as nifedipine have been used but have not been found to be effective.3 Antihistamines also have failed to control the lesions.11

Treatment of cold panniculitis is based on the prevention of further insult versus trying to cure the condition. Avoidance of cold and wind exposure as well as direct contact with ice are key methods in preventing cold panniculitis.

Our patient’s presentation of this condition was unique. Although cold panniculitis lesions usually develop 1 to 3 days after cold exposure, our patient did not develop lesions until 10 days following surgery. The cold therapy unit used by our patient was evaluated in our office and also by the manufacturer and was found to be functioning normally with no defects. The late onset of the lesions was attributed to limited application of the cold therapy unit; our patient used it for only 1 hour every night, whereas application for 6 to 8 hours continuously is normally recommended. The lesions may have occurred sooner had the patient been using a solid ice pack versus the continuous cold circulating water of the cold therapy unit. Pathology was consistent with the patient’s history and physical examination indicating a diagnosis of cold panniculitis. The challenge of treatment was to alleviate the pain of the lesions as well as the postoperative shoulder pain without the aid of any form of cold therapy. The patient only needed a tincture of time, as the lesions resolved after 4 weeks. Patient education was provided on future prevention of this condition by avoiding exposure to cold or applying cold packs directly to the skin.

 

 

Acknowledgment

The authors thank the staff at the Office of Scientific Writing and Publication at the Marshfield Clinic Research Foundation, Wisconsin, for their editorial assistance in the preparation of this manuscript.

References

 

1. Peters MS, Su WP. Panniculitis. Dermatol Clin. 1992;10:37-57.

2. Patterson JW. Panniculitis. In: Bolognia J, Jorizzo J, Rapini R, eds. Dermatology. 2nd ed. St. Louis, MO: Mosby Elsevier; 2008:1515-1530.

3. Quesada-Cortés A, Campos-Muñoz L, Díaz-Díaz RM, et al. Cold panniculitis. Dermatol Clin. 2008;26:485-489.

4. Solomon LM, Beerman H. Cold panniculitis. Arch Dermatol. 1963;88:897-900.

5. Beacham BE, Cooper PH, Buchanan CS, et al. Equestrian cold panniculitis in women. Arch Dermatol. 1980;116:1025-1027.

6. Ter Poorten MC, Thiers BH. Panniculitis. Dermatol Clin. 2002;20:421-433.

7. Ter Poorten JC, Hebert AA, Ilkiw R. Cold panniculitis in a neonate. J Am Acad Dermatol. 1995;33(2, pt 2):383-385.

8. Page EH, Shear NH. Temperature-dependent skin disorders. J Am Acad Dermatol. 1988;18(5, pt 1):1003-1019.

9. Requena L, Sánchez Yus E. Panniculitis. part II. mostly lobular panniculitis. J Am Acad Dermatol. 2001;45:325-361.

10. Diaz Cascajo C, Borghi S, Weyers W. Panniculitis: definition of terms and diagnostic strategy. Am J Dermatopathol. 2000;22:530-549.

11. Duncan WC, Freeman RG, Heaton CL. Cold panniculitis. Arch Dermatol. 1966;94:722-724.

Article PDF
Author and Disclosure Information

 

Michelle M. Lipke, MPAS, PA-C; Jonathan E. Cutlan, MD; Ann C. Smith, MD

Ms. Lipke is from the Marshfield Clinic Wausau Center, Wisconsin. Drs. Cutlan and Smith are from the Marshfield Clinic, Wisconsin. Dr. Cutlan is from the Department of Lab-Pathology and Dr. Smith is from the Department of Dermatology.

The authors report no conflict of interest.

Correspondence: Ann C. Smith, MD, Department of Dermatology (4K5), Marshfield Clinic, 1000 N Oak Ave, Marshfield, WI 54449 (smith.ann@marshfieldclinic.org).

Issue
Cutis - 95(1)
Publications
Topics
Page Number
21-24
Legacy Keywords
adipose tissue, traumatic panniculitis, panniculitides, temperature-dependent skin disorders, cold therapy unit, temperature reaction
Sections
Author and Disclosure Information

 

Michelle M. Lipke, MPAS, PA-C; Jonathan E. Cutlan, MD; Ann C. Smith, MD

Ms. Lipke is from the Marshfield Clinic Wausau Center, Wisconsin. Drs. Cutlan and Smith are from the Marshfield Clinic, Wisconsin. Dr. Cutlan is from the Department of Lab-Pathology and Dr. Smith is from the Department of Dermatology.

The authors report no conflict of interest.

Correspondence: Ann C. Smith, MD, Department of Dermatology (4K5), Marshfield Clinic, 1000 N Oak Ave, Marshfield, WI 54449 (smith.ann@marshfieldclinic.org).

Author and Disclosure Information

 

Michelle M. Lipke, MPAS, PA-C; Jonathan E. Cutlan, MD; Ann C. Smith, MD

Ms. Lipke is from the Marshfield Clinic Wausau Center, Wisconsin. Drs. Cutlan and Smith are from the Marshfield Clinic, Wisconsin. Dr. Cutlan is from the Department of Lab-Pathology and Dr. Smith is from the Department of Dermatology.

The authors report no conflict of interest.

Correspondence: Ann C. Smith, MD, Department of Dermatology (4K5), Marshfield Clinic, 1000 N Oak Ave, Marshfield, WI 54449 (smith.ann@marshfieldclinic.org).

Article PDF
Article PDF
Related Articles

The panniculitides can be a complex dermatologic entity for both dermatologists and dermatopathologists. The history, clinical examination, and histology need to be correlated to arrive at a differential diagnosis that will ultimately provide a diagnosis for the subcutaneous lesions. Panniculitis is an inflammation of the subcutaneous adipose tissue and can be associated with systemic diseases. According to Peters and Su,1 “Anatomic location of lesions, presence or absence of ulceration, occurrence of lipoatrophy, history of trauma, association with immunologic or metabolic disorders, and age of the patient are important clinical data to consider in conjunction with the microscopic features.” The panniculitides histologic differences may be subtle because they all include septal and lobular components, but one is usually more dominant in leading to a diagnosis along with the clinical findings.2

Cold panniculitis is a form of traumatic panniculitis. We present a unique case of this condition that was caused by use of a cold therapy unit following surgery to relieve pain.

Case Report

A 37-year-old woman presented for a routine postoperative visit 15 days following arthroscopic repair of a superior labrum anterior posterior tear in the left shoulder with a single suture anchor. The patient reported a rash that had developed 10 days postoperatively on the left upper arm. The rash started as red dots that progressively became larger, painful, and warm to the touch. The rash did not spread anywhere else on the patient’s body, and she denied fever, chills, and pruritus. She had tried using diphenhydramine without relief. The only new medication the patient had started prior to the eruption was oxycodone, which was initiated immediately following surgery. Prior to surgery, the entire left upper extremity including the shoulder had been prepared with a preoperative surgical skin antiseptic. There were no visible signs of the antiseptic on the skin at the time of presentation. The patient reported that she had applied a cold therapy unit to the left upper arm over her clothing for 1 hour every night since surgery. The cold therapy unit frequently is used to help decrease postoperative pain, swelling, inflammation, and narcotic use following surgical procedures.

Physical examination revealed multiple well-defined, erythematous, tender, indurated, warm nodules on the lateral aspect of the left upper arm (Figure 1). No other areas of eruption were noted on the body, and there was no swelling of the left elbow, forearm, wrist, or hand. The left upper extremity demonstrated intact sensation, rapid capillary refill, and a palpable radial pulse. Her weight was 230.1 lb with a body mass index of 35.

 

Figure 1. Multiple well-defined, erythematous, tender, indurated nodules presented on the lateral aspect of the left upper arm.

Figure 2. Punch biopsy showed a superficial and deep perivascular and periadnexal lymphoid infiltrate with involvement of the subcutis (H&E, original magnification ×40).

A 5-mm punch biopsy from a nodule on the left upper arm was performed, and pathology demonstrated vacuolar interface changes with patchy parakeratosis, spongiosis, and dyskeratosis on staining with hematoxylin and eosin. Pandermal and subcutaneous perivascular, periadnexal, and mild interstitial lymphohistiocytic infiltrate with occasional neutrophils and eosinophils were noted (Figure 2). The inflammation extended to the subcutaneous fat involving both septae and lobules with a primarily lobular distribution.

Clinical and pathologic correlation was required to arrive at a definitive diagnosis of cold panniculitis. The epidermal and dermal changes were consistent with a pernio or chilblains type of insult, and the septal and lobular panniculitis was indicative of cold panniculitis. The patient was advised to discontinue use of the cold therapy device as well as any other form of icing of the left shoulder or arm. She continued the oxycodone for pain control. Four weeks postoperatively, only desquamation remained where the nodules had previously appeared, which also eventually resolved.

Comment

Infants and small children are more predisposed to cold panniculitis than adults. In their 2008 review, Quesada-Cortés et al3 found the first report of cold panniculitis by Hochsinger in 1902 in a German pediatric journal, followed by reports from Lemez in 1928 and Haxthausen in 1941, which subsequently described similar cases in infants. Adult cases were not reported until 1963 by Solomon and Beerman4 and then in 1980 by Beacham et al.5

Etiologies for children have included popsicles, ice packs applied to the face to control supraventricular tachycardia or to the lower extremities after vaccinations, and cold weather exposure.6 The chemical composition of fat tissue plays a role in pediatric patients. According to Quesada-Cortés et al,3 subcutaneous fat in newborns is rich in saturated oils such as palmitic and stearic acids that have a higher solidification point. A small decrease in an infant’s temperature may result in crystallization of fat. The subcutaneous fat tends to become more unsaturated with aging with more oleic acid, and the solidification temperature diminishes.7

 

 

Cryoglobulins and cold agglutinins have not been demonstrated to be a cause of cold panniculitis in infants.7 Severe cold exposure or predisposition to certain conditions such as cryofibrinogenemia may occur in some adult patients. Gender does not seem to be a factor in children; however, in adults, women tend to be more predisposed to cold panniculitis secondary to obesity and participation in activities such as cycling, motorcycling, or horseback riding in cold conditions.3

On clinical examination, cold panniculitis features erythematous, firm, tender nodules on the cheeks and chin in infants and small children.2 These areas often are exposed to cold weather or wind because they typically are not covered with protective clothing.3 Nodules generally occur 1 to 3 days following exposure to cold and usually resolve spontaneously within 2 weeks.8 Popsicle panniculitis is characterized by a reddish discoloration on both cheeks 1 or 2 days after sucking on popsicles or ice cubes. This reaction can be reproduced in a half day by applying an ice cube to the volar forearm for 2 minutes, which can help diagnose and differentiate this subset of cold panniuculits.3 The red area in cold panniculitis eventually turns purple, becomes less indurated, and fades in approximately 3 months, but occasionally residual hyperpigmentation will last for a few months. Ice packs used as treatment of congenital cardiac arrhythmias in some cardiac surgeries and as surface cooling for management of birth asphyxia can produce a similar physical presentation.3

Equestrian panniculitis is characterized by erythematous, violaceous, tender plaques on the upper lateral thighs of young females who participate in horseback riding in the winter while wearing tight-fitting pants.2,5 These plaques typically occur within several hours and over the next week become painful, violaceous, and indurated or develop red nodules or plaques that can ulcerate or become crusted.3 These lesions usually will spontaneously resolve within 3 weeks, but new areas may occur again during the winter on further exposure with occasional persistent hyperpigmentation. These areas usually disappear at the end of winter with warmer weather or when horseback riding is discontinued. Perniosis also needs to be considered in the differential diagnosis due to the location and appearance of the lesions.3

It is important to obtain the correct specimen for biopsy. According to Peters and Su,1 a deep excisional biopsy that includes multiple fat lobules in addition to dermis and epidermis is critical. On histology, cold panniculitis usually demonstrates a primarily lobular inflammation. There typically is a superficial and deep perivascular lymphocytic infiltrate in the papillary dermis with edema noted in the connective tissue around the eccrine glands that can appear similar to perniosis on histopathology.9 Deposition of mucin, focal panniculitis surrounded by fatty tissue without inflammatory changes within the same field, and fat necrosis with pseudocysts and numerous lipophages also are characteristic features of cold panniculitis.10 Needlelike clefts are not present in cold panniculitis but appear in subcutaneous fat necrosis of the newborn.1

Different treatments have been tried, but no substantial impact on the rate of dissipation of the lesions has been noted. The plaques slowly resolve without scarring over 2 to 3 weeks if the cold source is removed.2 Application of a heating pad to the affected area has been used with limited success. Vasodilators such as nifedipine have been used but have not been found to be effective.3 Antihistamines also have failed to control the lesions.11

Treatment of cold panniculitis is based on the prevention of further insult versus trying to cure the condition. Avoidance of cold and wind exposure as well as direct contact with ice are key methods in preventing cold panniculitis.

Our patient’s presentation of this condition was unique. Although cold panniculitis lesions usually develop 1 to 3 days after cold exposure, our patient did not develop lesions until 10 days following surgery. The cold therapy unit used by our patient was evaluated in our office and also by the manufacturer and was found to be functioning normally with no defects. The late onset of the lesions was attributed to limited application of the cold therapy unit; our patient used it for only 1 hour every night, whereas application for 6 to 8 hours continuously is normally recommended. The lesions may have occurred sooner had the patient been using a solid ice pack versus the continuous cold circulating water of the cold therapy unit. Pathology was consistent with the patient’s history and physical examination indicating a diagnosis of cold panniculitis. The challenge of treatment was to alleviate the pain of the lesions as well as the postoperative shoulder pain without the aid of any form of cold therapy. The patient only needed a tincture of time, as the lesions resolved after 4 weeks. Patient education was provided on future prevention of this condition by avoiding exposure to cold or applying cold packs directly to the skin.

 

 

Acknowledgment

The authors thank the staff at the Office of Scientific Writing and Publication at the Marshfield Clinic Research Foundation, Wisconsin, for their editorial assistance in the preparation of this manuscript.

The panniculitides can be a complex dermatologic entity for both dermatologists and dermatopathologists. The history, clinical examination, and histology need to be correlated to arrive at a differential diagnosis that will ultimately provide a diagnosis for the subcutaneous lesions. Panniculitis is an inflammation of the subcutaneous adipose tissue and can be associated with systemic diseases. According to Peters and Su,1 “Anatomic location of lesions, presence or absence of ulceration, occurrence of lipoatrophy, history of trauma, association with immunologic or metabolic disorders, and age of the patient are important clinical data to consider in conjunction with the microscopic features.” The panniculitides histologic differences may be subtle because they all include septal and lobular components, but one is usually more dominant in leading to a diagnosis along with the clinical findings.2

Cold panniculitis is a form of traumatic panniculitis. We present a unique case of this condition that was caused by use of a cold therapy unit following surgery to relieve pain.

Case Report

A 37-year-old woman presented for a routine postoperative visit 15 days following arthroscopic repair of a superior labrum anterior posterior tear in the left shoulder with a single suture anchor. The patient reported a rash that had developed 10 days postoperatively on the left upper arm. The rash started as red dots that progressively became larger, painful, and warm to the touch. The rash did not spread anywhere else on the patient’s body, and she denied fever, chills, and pruritus. She had tried using diphenhydramine without relief. The only new medication the patient had started prior to the eruption was oxycodone, which was initiated immediately following surgery. Prior to surgery, the entire left upper extremity including the shoulder had been prepared with a preoperative surgical skin antiseptic. There were no visible signs of the antiseptic on the skin at the time of presentation. The patient reported that she had applied a cold therapy unit to the left upper arm over her clothing for 1 hour every night since surgery. The cold therapy unit frequently is used to help decrease postoperative pain, swelling, inflammation, and narcotic use following surgical procedures.

Physical examination revealed multiple well-defined, erythematous, tender, indurated, warm nodules on the lateral aspect of the left upper arm (Figure 1). No other areas of eruption were noted on the body, and there was no swelling of the left elbow, forearm, wrist, or hand. The left upper extremity demonstrated intact sensation, rapid capillary refill, and a palpable radial pulse. Her weight was 230.1 lb with a body mass index of 35.

 

Figure 1. Multiple well-defined, erythematous, tender, indurated nodules presented on the lateral aspect of the left upper arm.

Figure 2. Punch biopsy showed a superficial and deep perivascular and periadnexal lymphoid infiltrate with involvement of the subcutis (H&E, original magnification ×40).

A 5-mm punch biopsy from a nodule on the left upper arm was performed, and pathology demonstrated vacuolar interface changes with patchy parakeratosis, spongiosis, and dyskeratosis on staining with hematoxylin and eosin. Pandermal and subcutaneous perivascular, periadnexal, and mild interstitial lymphohistiocytic infiltrate with occasional neutrophils and eosinophils were noted (Figure 2). The inflammation extended to the subcutaneous fat involving both septae and lobules with a primarily lobular distribution.

Clinical and pathologic correlation was required to arrive at a definitive diagnosis of cold panniculitis. The epidermal and dermal changes were consistent with a pernio or chilblains type of insult, and the septal and lobular panniculitis was indicative of cold panniculitis. The patient was advised to discontinue use of the cold therapy device as well as any other form of icing of the left shoulder or arm. She continued the oxycodone for pain control. Four weeks postoperatively, only desquamation remained where the nodules had previously appeared, which also eventually resolved.

Comment

Infants and small children are more predisposed to cold panniculitis than adults. In their 2008 review, Quesada-Cortés et al3 found the first report of cold panniculitis by Hochsinger in 1902 in a German pediatric journal, followed by reports from Lemez in 1928 and Haxthausen in 1941, which subsequently described similar cases in infants. Adult cases were not reported until 1963 by Solomon and Beerman4 and then in 1980 by Beacham et al.5

Etiologies for children have included popsicles, ice packs applied to the face to control supraventricular tachycardia or to the lower extremities after vaccinations, and cold weather exposure.6 The chemical composition of fat tissue plays a role in pediatric patients. According to Quesada-Cortés et al,3 subcutaneous fat in newborns is rich in saturated oils such as palmitic and stearic acids that have a higher solidification point. A small decrease in an infant’s temperature may result in crystallization of fat. The subcutaneous fat tends to become more unsaturated with aging with more oleic acid, and the solidification temperature diminishes.7

 

 

Cryoglobulins and cold agglutinins have not been demonstrated to be a cause of cold panniculitis in infants.7 Severe cold exposure or predisposition to certain conditions such as cryofibrinogenemia may occur in some adult patients. Gender does not seem to be a factor in children; however, in adults, women tend to be more predisposed to cold panniculitis secondary to obesity and participation in activities such as cycling, motorcycling, or horseback riding in cold conditions.3

On clinical examination, cold panniculitis features erythematous, firm, tender nodules on the cheeks and chin in infants and small children.2 These areas often are exposed to cold weather or wind because they typically are not covered with protective clothing.3 Nodules generally occur 1 to 3 days following exposure to cold and usually resolve spontaneously within 2 weeks.8 Popsicle panniculitis is characterized by a reddish discoloration on both cheeks 1 or 2 days after sucking on popsicles or ice cubes. This reaction can be reproduced in a half day by applying an ice cube to the volar forearm for 2 minutes, which can help diagnose and differentiate this subset of cold panniuculits.3 The red area in cold panniculitis eventually turns purple, becomes less indurated, and fades in approximately 3 months, but occasionally residual hyperpigmentation will last for a few months. Ice packs used as treatment of congenital cardiac arrhythmias in some cardiac surgeries and as surface cooling for management of birth asphyxia can produce a similar physical presentation.3

Equestrian panniculitis is characterized by erythematous, violaceous, tender plaques on the upper lateral thighs of young females who participate in horseback riding in the winter while wearing tight-fitting pants.2,5 These plaques typically occur within several hours and over the next week become painful, violaceous, and indurated or develop red nodules or plaques that can ulcerate or become crusted.3 These lesions usually will spontaneously resolve within 3 weeks, but new areas may occur again during the winter on further exposure with occasional persistent hyperpigmentation. These areas usually disappear at the end of winter with warmer weather or when horseback riding is discontinued. Perniosis also needs to be considered in the differential diagnosis due to the location and appearance of the lesions.3

It is important to obtain the correct specimen for biopsy. According to Peters and Su,1 a deep excisional biopsy that includes multiple fat lobules in addition to dermis and epidermis is critical. On histology, cold panniculitis usually demonstrates a primarily lobular inflammation. There typically is a superficial and deep perivascular lymphocytic infiltrate in the papillary dermis with edema noted in the connective tissue around the eccrine glands that can appear similar to perniosis on histopathology.9 Deposition of mucin, focal panniculitis surrounded by fatty tissue without inflammatory changes within the same field, and fat necrosis with pseudocysts and numerous lipophages also are characteristic features of cold panniculitis.10 Needlelike clefts are not present in cold panniculitis but appear in subcutaneous fat necrosis of the newborn.1

Different treatments have been tried, but no substantial impact on the rate of dissipation of the lesions has been noted. The plaques slowly resolve without scarring over 2 to 3 weeks if the cold source is removed.2 Application of a heating pad to the affected area has been used with limited success. Vasodilators such as nifedipine have been used but have not been found to be effective.3 Antihistamines also have failed to control the lesions.11

Treatment of cold panniculitis is based on the prevention of further insult versus trying to cure the condition. Avoidance of cold and wind exposure as well as direct contact with ice are key methods in preventing cold panniculitis.

Our patient’s presentation of this condition was unique. Although cold panniculitis lesions usually develop 1 to 3 days after cold exposure, our patient did not develop lesions until 10 days following surgery. The cold therapy unit used by our patient was evaluated in our office and also by the manufacturer and was found to be functioning normally with no defects. The late onset of the lesions was attributed to limited application of the cold therapy unit; our patient used it for only 1 hour every night, whereas application for 6 to 8 hours continuously is normally recommended. The lesions may have occurred sooner had the patient been using a solid ice pack versus the continuous cold circulating water of the cold therapy unit. Pathology was consistent with the patient’s history and physical examination indicating a diagnosis of cold panniculitis. The challenge of treatment was to alleviate the pain of the lesions as well as the postoperative shoulder pain without the aid of any form of cold therapy. The patient only needed a tincture of time, as the lesions resolved after 4 weeks. Patient education was provided on future prevention of this condition by avoiding exposure to cold or applying cold packs directly to the skin.

 

 

Acknowledgment

The authors thank the staff at the Office of Scientific Writing and Publication at the Marshfield Clinic Research Foundation, Wisconsin, for their editorial assistance in the preparation of this manuscript.

References

 

1. Peters MS, Su WP. Panniculitis. Dermatol Clin. 1992;10:37-57.

2. Patterson JW. Panniculitis. In: Bolognia J, Jorizzo J, Rapini R, eds. Dermatology. 2nd ed. St. Louis, MO: Mosby Elsevier; 2008:1515-1530.

3. Quesada-Cortés A, Campos-Muñoz L, Díaz-Díaz RM, et al. Cold panniculitis. Dermatol Clin. 2008;26:485-489.

4. Solomon LM, Beerman H. Cold panniculitis. Arch Dermatol. 1963;88:897-900.

5. Beacham BE, Cooper PH, Buchanan CS, et al. Equestrian cold panniculitis in women. Arch Dermatol. 1980;116:1025-1027.

6. Ter Poorten MC, Thiers BH. Panniculitis. Dermatol Clin. 2002;20:421-433.

7. Ter Poorten JC, Hebert AA, Ilkiw R. Cold panniculitis in a neonate. J Am Acad Dermatol. 1995;33(2, pt 2):383-385.

8. Page EH, Shear NH. Temperature-dependent skin disorders. J Am Acad Dermatol. 1988;18(5, pt 1):1003-1019.

9. Requena L, Sánchez Yus E. Panniculitis. part II. mostly lobular panniculitis. J Am Acad Dermatol. 2001;45:325-361.

10. Diaz Cascajo C, Borghi S, Weyers W. Panniculitis: definition of terms and diagnostic strategy. Am J Dermatopathol. 2000;22:530-549.

11. Duncan WC, Freeman RG, Heaton CL. Cold panniculitis. Arch Dermatol. 1966;94:722-724.

References

 

1. Peters MS, Su WP. Panniculitis. Dermatol Clin. 1992;10:37-57.

2. Patterson JW. Panniculitis. In: Bolognia J, Jorizzo J, Rapini R, eds. Dermatology. 2nd ed. St. Louis, MO: Mosby Elsevier; 2008:1515-1530.

3. Quesada-Cortés A, Campos-Muñoz L, Díaz-Díaz RM, et al. Cold panniculitis. Dermatol Clin. 2008;26:485-489.

4. Solomon LM, Beerman H. Cold panniculitis. Arch Dermatol. 1963;88:897-900.

5. Beacham BE, Cooper PH, Buchanan CS, et al. Equestrian cold panniculitis in women. Arch Dermatol. 1980;116:1025-1027.

6. Ter Poorten MC, Thiers BH. Panniculitis. Dermatol Clin. 2002;20:421-433.

7. Ter Poorten JC, Hebert AA, Ilkiw R. Cold panniculitis in a neonate. J Am Acad Dermatol. 1995;33(2, pt 2):383-385.

8. Page EH, Shear NH. Temperature-dependent skin disorders. J Am Acad Dermatol. 1988;18(5, pt 1):1003-1019.

9. Requena L, Sánchez Yus E. Panniculitis. part II. mostly lobular panniculitis. J Am Acad Dermatol. 2001;45:325-361.

10. Diaz Cascajo C, Borghi S, Weyers W. Panniculitis: definition of terms and diagnostic strategy. Am J Dermatopathol. 2000;22:530-549.

11. Duncan WC, Freeman RG, Heaton CL. Cold panniculitis. Arch Dermatol. 1966;94:722-724.

Issue
Cutis - 95(1)
Issue
Cutis - 95(1)
Page Number
21-24
Page Number
21-24
Publications
Publications
Topics
Article Type
Display Headline
Cold Panniculitis: Delayed Onset in an Adult
Display Headline
Cold Panniculitis: Delayed Onset in an Adult
Legacy Keywords
adipose tissue, traumatic panniculitis, panniculitides, temperature-dependent skin disorders, cold therapy unit, temperature reaction
Legacy Keywords
adipose tissue, traumatic panniculitis, panniculitides, temperature-dependent skin disorders, cold therapy unit, temperature reaction
Sections
Inside the Article

     Practice Points

 

  • ­Cold panniculitis is a form of traumatic panniculitis.
  • ­Cold panniculitis often appears on the cheeks and chin, areas that are exposed to cold weather or wind because they are not covered with protective clothing, in infants and small children.
  • ­Treatment of cold panniculitis is based on the prevention of further insult. 
Disallow All Ads
Article PDF Media

Aspergillus nidulans Causing Primary Cutaneous Aspergillosis in an Immunocompetent Patient

Article Type
Changed
Display Headline
Aspergillus nidulans Causing Primary Cutaneous Aspergillosis in an Immunocompetent Patient

To the Editor:

Cutaneous aspergillosis mostly has been reported in immunosuppressed hosts and usually is caused by Aspergillus flavus or Aspergillus fumigatus. We report the occurrence of primary cutaneous aspergillosis (PCA) caused by a relatively rare species, Aspergillus nidulans, in a middle-aged patient without overt immunosuppression or history of trauma.

A 57-year-old woman was referred to the dermatology outpatient department for evaluation of a lesion on the right hand of 1 month's duration. On examination the lesion measured approximately 4×3 cm with central necrosis (Figure 1). Her medical history was unremarkable and routine laboratory test results were within reference range.

Figure 1. Cutaneous lesion on the right hand with central necrosis.

Figure 2. Culture of Aspergillus nidulans on Sabouraud dextrose agar.

The patient was an agricultural worker with no history of trauma. Her history was unremarkable. A 20% potassium hydroxide mount of the tissue revealed septate, branched, hyaline hyphae. A soft, wooly, greenish brown growth was observed after 3 days of incubation on Sabouraud dextrose agar (Figure 2). No growth was observed on dermatophyte test medium. A lactophenol cotton blue mount revealed columnar conidial heads with brown, short, smooth-walled conidiophores (Figures 3–6). Vesicles were hemispheric and small (8–12 µm in diameter), with metulae and phialides occurring in the upper portion. Conidia were globose (3–4 µm) and rough. Based on these findings the fungus was identified as A nidulans. The patient did not respond to daily oral ketoconazole, and after 1 month of therapy the lesion did not regress. She was eventually treated with oral itraconazole and the lesion completely healed within 15 weeks.

Figure 3. Globose and thick-walled conidia of Aspergillus nidulans (lactophenol cotton blue mount, original magnification ×40).

Figure 4. Conidial head of Aspergillus nidulans (lactophenol cotton blue mount, original magnification ×40).

Figure 5. Columnar heads of Aspergillus nidulans (lactophenol cotton blue mount, original magnifi-cation ×40).

Figure 6. Cleistothecium of Aspergillus nidulans (lactophenol cotton blue mount, original magnification ×40) with hulle cells (arrow).

An overwhelming majority of the cases of cutaneous aspergillosis have been reported either in immunocompromised hosts (ie, leukemia, cutaneous T-cell lymphoma, Hodgkin disease, human immunodeficiency virus/AIDS, solid-organ or hematopoietic stem cell transplant recipients) or in patients with contributing risk factors (ie, severe burns, diabetes mellitus, preterm or underweight neonates, elderly patients). Two outbreaks of this condition have been reported in neonatal intensive care units, with the source of contamination being linked to nonsterile disposable gloves, incubators, and humidity chambers.1,2 However, PCA is a relatively rare condition and often is associated with disruption of dermal integrity by trauma or maceration, followed by colonization of the wound by Aspergillus spores that are ubiquitously present in soil and decomposed vegetation.3-5 Our case was remarkable, as the patient was not immunosuppressed and did not have a history of trauma. However, we surmise that fungal inoculation might have inadvertently occurred through some trivial trauma sustained through her professional work.

The 2 species that have most commonly been associated with PCA are A flavus and A fumigatus.6,7 There have been isolated reports of PCA caused by other organisms such as Aspergillus niger,8,9 Aspergillus terreus,10Aspergillus ustus,11 or Aspergillus calidoustus.12 In a report of a neutropenic 56-year-old patient suffering from acute myeloblastic leukemia, PCA developed in association with a double-lumen Hickman catheter after a period of prolonged hospitalization.13 A study by the National Institutes of Health (1976-1997) revealed 6 life-threatening cases of A nidulans infection in patients with chronic granulomatous disease.14

We did not perform antifungal susceptibility testing on the isolate in our patient. However, we observed disease that was refractory to ketoconazole therapy but successfully resolved with oral itraconazole. Antifungal susceptibility was noted in a large number of reported cases of Aspergillus infections that were resistant to conventional treatment, such as voriconazole, itraconazole, and amphotericin B.15 Thus antifungal susceptibility testing is necessary before starting treatment. There also have been reports of recurrence of cutaneous aspergillosis following incomplete and irregular treatment.16 Our case of PCA also failed to respond to ketoconazole therapy, thus stressing the need for thorough mycological characterization, including the determination of an antifungal susceptibility profile, for successful and complete management of this condition.

Acknowledgment
The authors would like to thank Arunaloke Chakraborti, MD, Chandigarh, India, for the help extended for identification of the fungus.

References
  1. Stock C, Veyrier M, Raberin H, et al. Severe cutaneous aspergillosis in a premature neonate linked to nonsterile disposable glove contamination [published online ahead of print August 31, 2011]? Am J Infect Control. 2012;40:465-467.
  2. Etienne KA, Subudhi CP, Chadwick PR, et al. Investigation of a cluster of cutaneous aspergillosis in a neonatal intensive care unit [published online ahead of print August 12, 2011]. J Hosp Infect. 2011;79:344-348.
  3. Isaac M. Cutaneous aspergillosis. Dermatol Clin. 1996;14:137-140.
  4. Cahill KM, Mofty AM, Kawaguchi TP. Primary cutaneous aspergillosis. Arch Dermatol. 1967;96:545-547.
  5. Carlile JR, Millet RE, Cho CT, et al. Primary cutaneous aspergillosis in a leukemic child. Arch Dermatol. 1978;114:78-80.
  6. John PU, Shadomy HJ. Deep fungal infections. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al, eds. Dermatology in General Medicine. New York, NY: McGraw Hill; 1987:2266-2268.
  7. Chakrabarti A, Gupta V, Biswas G, et al. Primary cutaneous aspergillosis: our experience in 10 years. J Infect. 1998;37:24-27.
  8. Robinson A, Fien S, Grassi MA. Nonhealing scalp wound infected with Aspergillus niger in an elderly patient. Cutis. 2011;87:197-200.
  9. Thomas LM, Rand HK, Miller JL, et al. Primary cutaneous aspergillosis in a patient with a solid organ transplant: case report and review of the literature. Cutis. 2008;81:127-130.
  10. Yuanjie Z, Jingxia D, Hai W, et al. Primary cutaneous aspergillosis in a patient with cutaneous T-cell lymphoma [published online ahead of print October 22, 2008]. Mycoses. 2009;52:462-464.
  11. Krishnan-Natesan S, Chandrasekar PH, Manavathu EK, et al. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine [published online ahead of print October 7, 2008]. Diagn Microbiol Infect Dis. 2008;62:443-446.
  12. Sato Y, Suzino K, Suzuki A, et al. Case of primary cutaneous Aspergillus calidoustus infection caused by nerve block therapy [in Japanese]. Med Mycol J. 2011;52:239-244.
  13. Lucas GM, Tucker P, Merz WG. Primary cutaneous Aspergillus nidulans infection associated with a Hickman catheter in a patient with neutropenia. Clin Infect Dis. 1999;29:1594-1596.
  14. Segal BH, DeCarlo ES, Kwon-Chung KJ, et al. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore). 1998;77:345-354.
  15. Woodruff CA, Hebert AA. Neonatal primary cutaneous aspergillosis: case report and review of the literature. Pediatr Dermatol. 2002;19:439-444.
  16. Mohapatra S, Xess I, Swetha JV, et al. Primary cutaneous aspergillosis due to Aspergillus niger in an immunocompetent patient. Indian J Med Microbiol. 2009;27:367-370.
Article PDF
Author and Disclosure Information

From the Himalayan Institute of Medical Sciences, Swami Ram Nagar, Jolly Grant, Dehradun, Uttarakhand, India. Drs. Kotwal, Biswas, Kakati, and Chauhan are from the Department of Microbiology. Dr. Roy is from the Department of Dermatology.

The authors report no conflict of interest.

Correspondence: Debasis Biswas, MD, Department of Microbiology, Himalayan Institute of Medical Sciences, Swami Ram Nagar, Jolly Grant, Dehradun, Uttarakhand 248140, India  (dbiswas71@rediffmail.com).

Issue
Cutis - 95(1)
Publications
Topics
Page Number
E1-E3
Legacy Keywords
primary cutaneous aspergillosis, aspergillus nidulans
Sections
Author and Disclosure Information

From the Himalayan Institute of Medical Sciences, Swami Ram Nagar, Jolly Grant, Dehradun, Uttarakhand, India. Drs. Kotwal, Biswas, Kakati, and Chauhan are from the Department of Microbiology. Dr. Roy is from the Department of Dermatology.

The authors report no conflict of interest.

Correspondence: Debasis Biswas, MD, Department of Microbiology, Himalayan Institute of Medical Sciences, Swami Ram Nagar, Jolly Grant, Dehradun, Uttarakhand 248140, India  (dbiswas71@rediffmail.com).

Author and Disclosure Information

From the Himalayan Institute of Medical Sciences, Swami Ram Nagar, Jolly Grant, Dehradun, Uttarakhand, India. Drs. Kotwal, Biswas, Kakati, and Chauhan are from the Department of Microbiology. Dr. Roy is from the Department of Dermatology.

The authors report no conflict of interest.

Correspondence: Debasis Biswas, MD, Department of Microbiology, Himalayan Institute of Medical Sciences, Swami Ram Nagar, Jolly Grant, Dehradun, Uttarakhand 248140, India  (dbiswas71@rediffmail.com).

Article PDF
Article PDF
Related Articles

To the Editor:

Cutaneous aspergillosis mostly has been reported in immunosuppressed hosts and usually is caused by Aspergillus flavus or Aspergillus fumigatus. We report the occurrence of primary cutaneous aspergillosis (PCA) caused by a relatively rare species, Aspergillus nidulans, in a middle-aged patient without overt immunosuppression or history of trauma.

A 57-year-old woman was referred to the dermatology outpatient department for evaluation of a lesion on the right hand of 1 month's duration. On examination the lesion measured approximately 4×3 cm with central necrosis (Figure 1). Her medical history was unremarkable and routine laboratory test results were within reference range.

Figure 1. Cutaneous lesion on the right hand with central necrosis.

Figure 2. Culture of Aspergillus nidulans on Sabouraud dextrose agar.

The patient was an agricultural worker with no history of trauma. Her history was unremarkable. A 20% potassium hydroxide mount of the tissue revealed septate, branched, hyaline hyphae. A soft, wooly, greenish brown growth was observed after 3 days of incubation on Sabouraud dextrose agar (Figure 2). No growth was observed on dermatophyte test medium. A lactophenol cotton blue mount revealed columnar conidial heads with brown, short, smooth-walled conidiophores (Figures 3–6). Vesicles were hemispheric and small (8–12 µm in diameter), with metulae and phialides occurring in the upper portion. Conidia were globose (3–4 µm) and rough. Based on these findings the fungus was identified as A nidulans. The patient did not respond to daily oral ketoconazole, and after 1 month of therapy the lesion did not regress. She was eventually treated with oral itraconazole and the lesion completely healed within 15 weeks.

Figure 3. Globose and thick-walled conidia of Aspergillus nidulans (lactophenol cotton blue mount, original magnification ×40).

Figure 4. Conidial head of Aspergillus nidulans (lactophenol cotton blue mount, original magnification ×40).

Figure 5. Columnar heads of Aspergillus nidulans (lactophenol cotton blue mount, original magnifi-cation ×40).

Figure 6. Cleistothecium of Aspergillus nidulans (lactophenol cotton blue mount, original magnification ×40) with hulle cells (arrow).

An overwhelming majority of the cases of cutaneous aspergillosis have been reported either in immunocompromised hosts (ie, leukemia, cutaneous T-cell lymphoma, Hodgkin disease, human immunodeficiency virus/AIDS, solid-organ or hematopoietic stem cell transplant recipients) or in patients with contributing risk factors (ie, severe burns, diabetes mellitus, preterm or underweight neonates, elderly patients). Two outbreaks of this condition have been reported in neonatal intensive care units, with the source of contamination being linked to nonsterile disposable gloves, incubators, and humidity chambers.1,2 However, PCA is a relatively rare condition and often is associated with disruption of dermal integrity by trauma or maceration, followed by colonization of the wound by Aspergillus spores that are ubiquitously present in soil and decomposed vegetation.3-5 Our case was remarkable, as the patient was not immunosuppressed and did not have a history of trauma. However, we surmise that fungal inoculation might have inadvertently occurred through some trivial trauma sustained through her professional work.

The 2 species that have most commonly been associated with PCA are A flavus and A fumigatus.6,7 There have been isolated reports of PCA caused by other organisms such as Aspergillus niger,8,9 Aspergillus terreus,10Aspergillus ustus,11 or Aspergillus calidoustus.12 In a report of a neutropenic 56-year-old patient suffering from acute myeloblastic leukemia, PCA developed in association with a double-lumen Hickman catheter after a period of prolonged hospitalization.13 A study by the National Institutes of Health (1976-1997) revealed 6 life-threatening cases of A nidulans infection in patients with chronic granulomatous disease.14

We did not perform antifungal susceptibility testing on the isolate in our patient. However, we observed disease that was refractory to ketoconazole therapy but successfully resolved with oral itraconazole. Antifungal susceptibility was noted in a large number of reported cases of Aspergillus infections that were resistant to conventional treatment, such as voriconazole, itraconazole, and amphotericin B.15 Thus antifungal susceptibility testing is necessary before starting treatment. There also have been reports of recurrence of cutaneous aspergillosis following incomplete and irregular treatment.16 Our case of PCA also failed to respond to ketoconazole therapy, thus stressing the need for thorough mycological characterization, including the determination of an antifungal susceptibility profile, for successful and complete management of this condition.

Acknowledgment
The authors would like to thank Arunaloke Chakraborti, MD, Chandigarh, India, for the help extended for identification of the fungus.

To the Editor:

Cutaneous aspergillosis mostly has been reported in immunosuppressed hosts and usually is caused by Aspergillus flavus or Aspergillus fumigatus. We report the occurrence of primary cutaneous aspergillosis (PCA) caused by a relatively rare species, Aspergillus nidulans, in a middle-aged patient without overt immunosuppression or history of trauma.

A 57-year-old woman was referred to the dermatology outpatient department for evaluation of a lesion on the right hand of 1 month's duration. On examination the lesion measured approximately 4×3 cm with central necrosis (Figure 1). Her medical history was unremarkable and routine laboratory test results were within reference range.

Figure 1. Cutaneous lesion on the right hand with central necrosis.

Figure 2. Culture of Aspergillus nidulans on Sabouraud dextrose agar.

The patient was an agricultural worker with no history of trauma. Her history was unremarkable. A 20% potassium hydroxide mount of the tissue revealed septate, branched, hyaline hyphae. A soft, wooly, greenish brown growth was observed after 3 days of incubation on Sabouraud dextrose agar (Figure 2). No growth was observed on dermatophyte test medium. A lactophenol cotton blue mount revealed columnar conidial heads with brown, short, smooth-walled conidiophores (Figures 3–6). Vesicles were hemispheric and small (8–12 µm in diameter), with metulae and phialides occurring in the upper portion. Conidia were globose (3–4 µm) and rough. Based on these findings the fungus was identified as A nidulans. The patient did not respond to daily oral ketoconazole, and after 1 month of therapy the lesion did not regress. She was eventually treated with oral itraconazole and the lesion completely healed within 15 weeks.

Figure 3. Globose and thick-walled conidia of Aspergillus nidulans (lactophenol cotton blue mount, original magnification ×40).

Figure 4. Conidial head of Aspergillus nidulans (lactophenol cotton blue mount, original magnification ×40).

Figure 5. Columnar heads of Aspergillus nidulans (lactophenol cotton blue mount, original magnifi-cation ×40).

Figure 6. Cleistothecium of Aspergillus nidulans (lactophenol cotton blue mount, original magnification ×40) with hulle cells (arrow).

An overwhelming majority of the cases of cutaneous aspergillosis have been reported either in immunocompromised hosts (ie, leukemia, cutaneous T-cell lymphoma, Hodgkin disease, human immunodeficiency virus/AIDS, solid-organ or hematopoietic stem cell transplant recipients) or in patients with contributing risk factors (ie, severe burns, diabetes mellitus, preterm or underweight neonates, elderly patients). Two outbreaks of this condition have been reported in neonatal intensive care units, with the source of contamination being linked to nonsterile disposable gloves, incubators, and humidity chambers.1,2 However, PCA is a relatively rare condition and often is associated with disruption of dermal integrity by trauma or maceration, followed by colonization of the wound by Aspergillus spores that are ubiquitously present in soil and decomposed vegetation.3-5 Our case was remarkable, as the patient was not immunosuppressed and did not have a history of trauma. However, we surmise that fungal inoculation might have inadvertently occurred through some trivial trauma sustained through her professional work.

The 2 species that have most commonly been associated with PCA are A flavus and A fumigatus.6,7 There have been isolated reports of PCA caused by other organisms such as Aspergillus niger,8,9 Aspergillus terreus,10Aspergillus ustus,11 or Aspergillus calidoustus.12 In a report of a neutropenic 56-year-old patient suffering from acute myeloblastic leukemia, PCA developed in association with a double-lumen Hickman catheter after a period of prolonged hospitalization.13 A study by the National Institutes of Health (1976-1997) revealed 6 life-threatening cases of A nidulans infection in patients with chronic granulomatous disease.14

We did not perform antifungal susceptibility testing on the isolate in our patient. However, we observed disease that was refractory to ketoconazole therapy but successfully resolved with oral itraconazole. Antifungal susceptibility was noted in a large number of reported cases of Aspergillus infections that were resistant to conventional treatment, such as voriconazole, itraconazole, and amphotericin B.15 Thus antifungal susceptibility testing is necessary before starting treatment. There also have been reports of recurrence of cutaneous aspergillosis following incomplete and irregular treatment.16 Our case of PCA also failed to respond to ketoconazole therapy, thus stressing the need for thorough mycological characterization, including the determination of an antifungal susceptibility profile, for successful and complete management of this condition.

Acknowledgment
The authors would like to thank Arunaloke Chakraborti, MD, Chandigarh, India, for the help extended for identification of the fungus.

References
  1. Stock C, Veyrier M, Raberin H, et al. Severe cutaneous aspergillosis in a premature neonate linked to nonsterile disposable glove contamination [published online ahead of print August 31, 2011]? Am J Infect Control. 2012;40:465-467.
  2. Etienne KA, Subudhi CP, Chadwick PR, et al. Investigation of a cluster of cutaneous aspergillosis in a neonatal intensive care unit [published online ahead of print August 12, 2011]. J Hosp Infect. 2011;79:344-348.
  3. Isaac M. Cutaneous aspergillosis. Dermatol Clin. 1996;14:137-140.
  4. Cahill KM, Mofty AM, Kawaguchi TP. Primary cutaneous aspergillosis. Arch Dermatol. 1967;96:545-547.
  5. Carlile JR, Millet RE, Cho CT, et al. Primary cutaneous aspergillosis in a leukemic child. Arch Dermatol. 1978;114:78-80.
  6. John PU, Shadomy HJ. Deep fungal infections. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al, eds. Dermatology in General Medicine. New York, NY: McGraw Hill; 1987:2266-2268.
  7. Chakrabarti A, Gupta V, Biswas G, et al. Primary cutaneous aspergillosis: our experience in 10 years. J Infect. 1998;37:24-27.
  8. Robinson A, Fien S, Grassi MA. Nonhealing scalp wound infected with Aspergillus niger in an elderly patient. Cutis. 2011;87:197-200.
  9. Thomas LM, Rand HK, Miller JL, et al. Primary cutaneous aspergillosis in a patient with a solid organ transplant: case report and review of the literature. Cutis. 2008;81:127-130.
  10. Yuanjie Z, Jingxia D, Hai W, et al. Primary cutaneous aspergillosis in a patient with cutaneous T-cell lymphoma [published online ahead of print October 22, 2008]. Mycoses. 2009;52:462-464.
  11. Krishnan-Natesan S, Chandrasekar PH, Manavathu EK, et al. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine [published online ahead of print October 7, 2008]. Diagn Microbiol Infect Dis. 2008;62:443-446.
  12. Sato Y, Suzino K, Suzuki A, et al. Case of primary cutaneous Aspergillus calidoustus infection caused by nerve block therapy [in Japanese]. Med Mycol J. 2011;52:239-244.
  13. Lucas GM, Tucker P, Merz WG. Primary cutaneous Aspergillus nidulans infection associated with a Hickman catheter in a patient with neutropenia. Clin Infect Dis. 1999;29:1594-1596.
  14. Segal BH, DeCarlo ES, Kwon-Chung KJ, et al. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore). 1998;77:345-354.
  15. Woodruff CA, Hebert AA. Neonatal primary cutaneous aspergillosis: case report and review of the literature. Pediatr Dermatol. 2002;19:439-444.
  16. Mohapatra S, Xess I, Swetha JV, et al. Primary cutaneous aspergillosis due to Aspergillus niger in an immunocompetent patient. Indian J Med Microbiol. 2009;27:367-370.
References
  1. Stock C, Veyrier M, Raberin H, et al. Severe cutaneous aspergillosis in a premature neonate linked to nonsterile disposable glove contamination [published online ahead of print August 31, 2011]? Am J Infect Control. 2012;40:465-467.
  2. Etienne KA, Subudhi CP, Chadwick PR, et al. Investigation of a cluster of cutaneous aspergillosis in a neonatal intensive care unit [published online ahead of print August 12, 2011]. J Hosp Infect. 2011;79:344-348.
  3. Isaac M. Cutaneous aspergillosis. Dermatol Clin. 1996;14:137-140.
  4. Cahill KM, Mofty AM, Kawaguchi TP. Primary cutaneous aspergillosis. Arch Dermatol. 1967;96:545-547.
  5. Carlile JR, Millet RE, Cho CT, et al. Primary cutaneous aspergillosis in a leukemic child. Arch Dermatol. 1978;114:78-80.
  6. John PU, Shadomy HJ. Deep fungal infections. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al, eds. Dermatology in General Medicine. New York, NY: McGraw Hill; 1987:2266-2268.
  7. Chakrabarti A, Gupta V, Biswas G, et al. Primary cutaneous aspergillosis: our experience in 10 years. J Infect. 1998;37:24-27.
  8. Robinson A, Fien S, Grassi MA. Nonhealing scalp wound infected with Aspergillus niger in an elderly patient. Cutis. 2011;87:197-200.
  9. Thomas LM, Rand HK, Miller JL, et al. Primary cutaneous aspergillosis in a patient with a solid organ transplant: case report and review of the literature. Cutis. 2008;81:127-130.
  10. Yuanjie Z, Jingxia D, Hai W, et al. Primary cutaneous aspergillosis in a patient with cutaneous T-cell lymphoma [published online ahead of print October 22, 2008]. Mycoses. 2009;52:462-464.
  11. Krishnan-Natesan S, Chandrasekar PH, Manavathu EK, et al. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine [published online ahead of print October 7, 2008]. Diagn Microbiol Infect Dis. 2008;62:443-446.
  12. Sato Y, Suzino K, Suzuki A, et al. Case of primary cutaneous Aspergillus calidoustus infection caused by nerve block therapy [in Japanese]. Med Mycol J. 2011;52:239-244.
  13. Lucas GM, Tucker P, Merz WG. Primary cutaneous Aspergillus nidulans infection associated with a Hickman catheter in a patient with neutropenia. Clin Infect Dis. 1999;29:1594-1596.
  14. Segal BH, DeCarlo ES, Kwon-Chung KJ, et al. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore). 1998;77:345-354.
  15. Woodruff CA, Hebert AA. Neonatal primary cutaneous aspergillosis: case report and review of the literature. Pediatr Dermatol. 2002;19:439-444.
  16. Mohapatra S, Xess I, Swetha JV, et al. Primary cutaneous aspergillosis due to Aspergillus niger in an immunocompetent patient. Indian J Med Microbiol. 2009;27:367-370.
Issue
Cutis - 95(1)
Issue
Cutis - 95(1)
Page Number
E1-E3
Page Number
E1-E3
Publications
Publications
Topics
Article Type
Display Headline
Aspergillus nidulans Causing Primary Cutaneous Aspergillosis in an Immunocompetent Patient
Display Headline
Aspergillus nidulans Causing Primary Cutaneous Aspergillosis in an Immunocompetent Patient
Legacy Keywords
primary cutaneous aspergillosis, aspergillus nidulans
Legacy Keywords
primary cutaneous aspergillosis, aspergillus nidulans
Sections
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media